exercise ; cardiovascular system

cox proportional hazards

EH




HF
follow-up
Cell ; Anand
doxorubicin
blood transfusions
FM

devices ; heart failure
dXA
Liver disease

HF ; pNA

Renal artery stenosis

heart transplant recipients
inhospital mortaliteit
molecular mechanism
tertiary referral centre
ec
HF




breathing ; heart beat

Retrospective cohort
heart failure ; Latin America


Heart rate

doctors
nutrition ; heart failure
Northwest United States

unilateral

heart failure
INTERvenTIONS

Heart failure

clin
Sci
trans

CHF treatments
autonomic balance
competitive
intermediate frailty
HFpEF
ST2

dodson

LV fibrosis ;ANS mice

Jehovahs Witness ; anemia
inpatient medical conditions
heart failure
cardiac transplantation
co ; mixed linear models
frailty ; HF
cognitive function
Heart failure ; cognitive impairment
concurrent HF ; HF
follow-up
cardiology ; hospital

Heart rate variability ; cardiac patients
Remote ischemic conditioning ; patients ; heart failure
air pollution ; heart failure

Sham-operated animals


policy
Compliance ; treatment

taxonomy
CHF
Heart failure ; uk

cardiovascular disease
HF ; MI

Heart failure ; disease
hemostasis

Caspase-3 gene expression ; heart failure
diuretic use ; heart failure
right heart failure ; pulmonary hypertension
Heart failure ; bisphosphonates

MR ; MS
hypertension
American ; Canadian ; HF
Heart rate ; arterial pressure

Chronic HF
Cardiac amyloidosis
Robot-assisted training ; heart failure patients

Internal reliability ; Cronbach
HFpEF
ejection fraction ; sex ; bNP
Pigs ; antiarrhythmic medication
therapy ; beta blockade
CHF patients ; intubated
circulatory arrest
functional capacity

systolic dysfunction


exercise ; heart failure
implanted monitoring devices

patient safety
HR ; Ea


RAS ; atherosclerosis
frailty ; heart failure
microRNAs ; heart failure ; disease management
cox regression analysis
PSSS
management ; heart failure ; ejection fraction
Cardiology ; bromodomain inhibition ; heart failure
AT
vasopressin ; congestive heart failure
mitral stenosis ; medical treatment ; heart failure
heart failure hospitalization ; cardiovascular death
Trastuzumab-related cardiotoxiciteit ; breast cancer
Devices ; heart failure ;HF
mortaliteit ; sts HM
pde2 ; HF
Nights spent in hospital
Heart failure
albumin level
lVET ; aortic pressure curve
physician continuity ; discharge
Medication regimen ; sst2

Cardiac symptoms ; children
spironolactone ; systolic heart failure
eRK1/2 molecular scaffolds ; heart pathology
Functional MS ; degenerative MR
chronic heart failure ; bisoprolol
Heart failure ;HF
cox proportional hazards
physician volume
Tolvaptan ; vasopressin ; receptor
arrhythmia-related costs
metric ; readmission metrics
readmission metric

median follow-up


black patients
et ; CHF
HF
follow-up

propensity
hgb level ; HRQoL
ejection fraction
biomarkers ; chronic heart failure
HF ; cardiovascular hospitalization
cardiac ; inflammatory biomarkers
mortaliteit
heart failure
Pharmacological treatment ; acute heart failure
heart failure
off-pump ; sternal sparing approach ; HeartMate II exchange
dialysis patients ; device implantation
Coronary angiography
Hemodynamic phenotype ; Fontan
MS ; echocardiography


heart failure ; cox proportional hazard analyses
Nordic walking ; heart failure
Psychometric testing ; Self-care of Heart Failure index
multiorgan failure ; sepsis
acute kidney injury
VO2max
cox proportional hazards
Seattle Heart Failure model

heart failure



abnormal cardiac t2
voordelen

HR ;HF

drug ; japan
biomarkers
mAIN oUTCOME ; tug test
ESRD
Heart failure ; left ventricular ejection fraction
mAIN oUTCOME ; readmissions
systolic HF

lVAD implantation
postsystolic function
medication ; resting hemodynamics

aac ; cardiac hypertrophy
AHA ; ESC
heart failure
keletal muscle abnormalities ; exercise capacity ; Fontan circulation
hospital ; heart failure
progressive disease ; hypertension ; kidney failure
chronic kidney disease ;CKd
gross income ; expenditure ; health per capita
hospital
abnormal HR variability ; cardiac death
circulation
toxiciteit ; systemic blood pressure



North America
cPGs
MS ; surgery

acute heart failure
patients ; heart failure
stand-alone diagnostic devices ;HF
heart failure
HF
endothelial function ; dilatation
Race ; spironolactone ; heart failure
heart failure ; cardiac rehabilitation
Rhythm- and rate-control
race ; exercise
voordelen ; anemia treatment ; heart disease
HF
Myocardial infarction ; Wistar rats
algorithms ; post- lVAD AI
AI
sinus rhythm ; AF
public reporting ; hospitals

care management ; telehealth ; medicare
diagnosti ; filling pressures
ingenuity
molecular level ; HF ; chromatin hyperacetylation

acute heart failure

MS
gLS ; CV events ; AF
deficit index

follow-up
mortaliteit
hospitals
QRs

CHF ; unilateral renal DNx ; cardiac autonomic balance
mitral regurgitation ; HF
renin-angiotensin-aldosterone system inhibitors ; heart failure
anaerobic threshold ; heart failure
MS
AF patients ; echocardiographic examination
patients ; disease
net economic savings ; cost
PVf ; recovery ; pb

congenital heart lesions
MS ;HF ; MS
ICU
bioinformatic analysis ; microarray ; genes ; heart failure
cardiovascular events
diuretic ;HF
CAD ; systolic HF
inflammation ; metabolism ; heart disease
sst2 concentrations ; benefit ; BB therapy
Heart block ; pulmonary artery snared ; BiVP

cRT ; dialysis-dependent patients
beta-blockers
CHF
RM
HF
Cardiac function ; pressure-volume conductance ; catheter system
idiopathic dilated cardiomyopathy
unfolded protein response ; cardiac sodium current ; systolic human heart failure
Hypoalbuminemia ; heart failure
hypertensive LV dysfunction ; MR ; MS
c d HF
angiotensin receptor ; neprilysin inhibitor ; heart failure
Western blot analysis ; immunohistochemistry ; electron microscopy
diastolic dysfunction ; peripheral artery disease
cardiomyopathy ; male sex ; mortaliteit
AF ; precipitating factor ; hFPEF
heart transplant ; ecCT
proteome ; HDL particles ; shotgun ;LC-MS
frailty ; HF
southeastern Minnesota residents ; HF
bundle branch block ; electrical activation sequence
hHF ; dPP-4 inhibitors ; drugs
proteins ;TAC
Cardiac cachexia ;cc
cardiac remodelling
dialysis patients
neurological ; cardiovascular events
coronary disease ; heart failure
fFM ; FM ; body weight ; CC
heart failure ; nurse leaders
Protective effects ; exercise training ;ET ; endothelial function
MS
social support ; exercise ; exercise
heart rate variation
cRF
Mediterranean ; DASh
rehospitalization
nitroxyl ; hno ; acute treatment ; heart failure
Cardiac-resynchronization therapy ; heart failure
odds ratios ; hospital clustering
lVET ; follow-up
blacks ; VO2
physician continuity ; death ; urgent readmission ; discharge ; heart failure
hFrEF ; HFpEF
hospital-to-Home ; hospital ; readmission reduction program ; congestive heart failure
sterf ; heart failure clinic
diabetes ; eEO-cFUs
patient safety
transplants
aerobic exercise
hospitals
trastuzumab-related CHF
hospitals
Peak VO2
pharmaceutically assisted

Coronary artery disease ;CAD ; systolic heart failure ;HF
hypoalbuminemia ; lVAD surgery
psoriasis ; atherosclerosis ; incident cardiovascular events ; Rotterdam Study
mortaliteit ;HF hospital admissions ; transplant ; ventricular assist device
Heart failure ; rheumatoid arthritis ; tNF antagonist
holosystolic murmur ; heart sound
CV ; death ; non-fatal stroke ; hospitalisation ; heart failure
HF ; haemodynamic ; neuronal stressors
deficit index ; biological phenotype ; mortality
right ventricular function ; body composition ; heart failure
Fat ; cachexia ; right ventricle ; heart failure
Atrial fibrillation ;AF ; heart failure
ecCT ; advanced heart failure therapy
heart transplantation ; left ventricular assist device
Exercise intolerance ; chronic heart failure
AVd ; VVD ; co ; free wall RS
resistin levels ; heart failure
eCGs ; electrocardiographers
left ventricular assist device ; right ventricular support
ESRD ; outpatients ;HF
Wilcoxon
subclinical atherosclerosis ; linear models
Renal artery stenosis ;RAS ; peripheral arterial disease
ecCT ; cardiac transplant recipients
eplerenone

extubated ; blood loss ; transfusion
techniek ; exchange malfunctioning HeartMate II lVADs
Heart failure ;HF ; cardiovascular hospitalization
VEGF inhibition ; b ; cardiac function ; remodeling
Î²-blocker ;bb ; sST2
miRNAs ; cardiac pathogenesis
cPET guiding exercise rehabilitation ; CHF
heart failure ; reduced ejection fraction
heart failure
Pediatric heart failure ;HF
regulatory subunit ;RI ;HF
follow-up medication
bromodomain proteins
mortaliteit
heart failure
bt ; DT

hypotension
biomarkers ; treatment ; HF
HF
ST2
economische
medications ; adults ; heart failure

coronary heart disease ; stroke ; heart failure
MLHF Questionnaire
septal defects
iCD-HF patients
renal denervation ; autonomic balance ; rabbits ; chronic heart failure

trastuzumab
germline DNA ; genotyped
Heart failure disease management
Renal DNx ; circulating plasma ; CHF-inv rabbits
HF

NP assessment ; ED patients
Cardiac hypertrophy ; energy metabolism
lVAD implantation
HDL-bound malondialdehyde ; ec
renal dysfunction ; post-transplant morbiditeit
derivation cohort ; CAD


hospital discharge
hospitals
anemia ; adults ; heart disease
Right atrial myxoma ; pulmonary embolism ; right heart failure
nfat ; mir-25 ; transcription factor ; hand2 ; heart failure
resistin ; ejection fraction
Orthotopic heart transplantation ; oHT ; heart failure
Myxomas ; right atrium ; pulmonary arterial vasculature
readmissions ; follow-up visits ; heart failure ; readmission
lVAS ; bridge to transplantation
Cardiac overexpression ; Mammalian enabled ; mena ; heart failure
cPCs ; functional capacity ; VO2
pump failure ; driveline injury ; isolated pump replacement
apoptosis ; chronic heart failure ; tachycardia
Nicorandil ; doxorubicin treatment
EH ; HFpEF
east ; rhythm control therapy ; cardiovascular complications ; AF
HF
diuretics ; congestive symptoms ; heart failure ;HF

soluble ; sp2 ; heart failure
Framingham Heart Study criteria ; HF ; EF
HF
acr ; CMS
band ; activated Caspase ; paced myocardium
frailty ; risk ; heart failure ; older adults ; body composition
hHF ; saxagliptin ; sitagliptin
Heart t2 ; heart failure ; arrhythmias
ischemic ; inflammatory abdominal problems ; MT
ED ; intubations ; congestive heart failure
medLine ; EMBAse ; cINAHL
aCP
coronary artery disease ;CAD


ED ; CHF
benefit
Medicare ; post-acute care transfer
Diet score ; vegetables ; nuts ; whole grain intake ; mortality

osprey
therapy
electronic databases ; world health Organization ; HF ; LA
deficit index ;SD
device implantation ; cRT
benefit
iron
remote monitoring ; hospital discharge ; patients met heart failure
LV ; filling pressure ; severe systolic HF
Soluble ST2 ; ambulatory patients ; heart failure
echocardiograms
Titin hypophosphorylation ; myocardial DD
right ventricular contractile reserve ; pulmonary hypertension
bottleneck stent ; chronic myocardial ischemia ; heart failure ; pigs
QT intervals ; SDQT
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
benefit ; RAS- ; Î²-blocker uptitration ; HFpEF
injections
pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis events
cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
noc ; admission to discharge
HRQoL ; exercise training ; hgb
inpatient records ; HF
skeletal muscle mass ; VO2
cardiac catheterization ; extubated
psychosocial factors ; exercise training ; heart failure ;HF
medical management ; heart failure ; children ; Canadian Cardiovascular Society

aRIC HF
atrial fibrillation ; pacemaker
mortaliteit ; iCD-HF
cardiovascular reason
AF-free probability ; catheter ablation ; sinus rhythm
body mass index ; cRF ; treadmill exercise testing
human myocardial tissue ; pka
paediatric cardiac transplants
ventricular-arterial coupling ; SV
diastolic failure ; cardiomyopathic restriction to flow
autonomic nervous system ; QTV
pneumonia ; surgical conditions
t1 mapping ; myocardial fibrosis


diet adherence ;SD
white
ethics Rounds

biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
Heart Failure ; Pathophysiology ; Medical Treatment Guidelines ; Nursing management
anemia ; heart disease ; clinical practice guideline ; American college of Physicians
heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure patients
renal disease ; systolic heart failure
rvPO ; BiVP ; co ; RS synchrony ; CS
renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
resistin ; anthracycline-induced cardiotoxiciteit
acute autonomic nervous system modulation ; QTV ; HF
Heart rate ; aortic blood flow ; doxorubicin

Myocardial pde2 expression ; HF
BAT ; sympathetic outflow ; parasympatische activity
echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
cardiovascular death ; HF hospitalization ; exercise training ; btes
chronic heart failure ; lipoprotein
Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ;CHf
parasympathetic neurotransmission ; acetylcholinesterase inhibition
LVEF ; long-term mortality
Mediterranean ; DASh diet scores ; mortality ; women ; heart failure ; Womens Health Initiative
Jehovah's Witness ; sickle cell disease ; anemia
miRNAs ; heart failure
dobutamine ; furosemide dose ; oxygen flow
Health Buddy Program ; ED
l-type ca2+ currents ; Rad ; congestive heart failure
cPCs ; diabetes
resistin levels ; anthracycline-treated breast cancer patients ; cardiotoxiciteit
left pulmonary artery ; pulmonary artery
mRI scanner ; heart failure

congestive heart failure ;CHf
muscle-wasting syndrome ; acquired heart failure ; Fontan
frailty ; elderly
ED visits ; CHF ; intubation rates
bisoprolol ; mortaliteit
Health Buddy Program ; telehealth system ; care management
Medicare
physician continuity
therapeutic ; heart failure
pss ; social support ; btes ; exercise
cardiac stress ; Î²-AR drive
chromatin subproteome ; mouse heart
co ; septal wall ; CS ; AVd ; free wall ; CS ; VVD
echocardiography ; ablation
death ; transplantation ; circulatory assist device
biventricular pacing ; left heart ; twist ; strain ; porcine model ; right heart failure
etiologic causes ; acute RV failure ; left ventricular dysfunction
cPCs ; functional capacity ; heart failure ;HF
protein kinase ; soluble guanylate cyclase ; contractile response
circulating progenitor cells ; heart failure patients
Stress doppler echocardiography ; pulmonary hypertension
systolic ; diastolic mitral leaflet
morbiditeit ; mortality ;HF
ctnt ; NT-probNP ; HF
student t test ; confidence intervals ;CIs
HF
inhospital mortality ; bNP level
Mortality ; aCS
right ventricle ;RV ; cardiac function
kosten ; heart failure ;HF
RV dysfunction ; weight loss ; fat ;lean body mass ratio
HR reduction ; beta blockers ; exercise capacity ; hFrEF
cardiopulmonary exercise ; heart failure
Canada
sympathetic activity ; i-miBG ; myocardial washout
myocardial diastolic dysfunction ;DD ; collagen deposition
sterf ; heart failure
ST2 level ;interquartile range
black race ; mortality
Nursing-sensitive outcome change scores ; older adults ; heart failure
diagnosti ; fluid overload
resistin ; chemotherapy-induced heart failure ; humanized male mice ; breast cancer

pressure ulcers ; surgical patients
HF ; valve plasty ; MS
PD ; refractory ; end-stage congestive heart failure ;CHf
insurance status
beta blockers ; heart failure
transcatheter ; surgery
futility ; safety monitoring board
complication
chelation regimens ; remove heart iron
MT ; abdominal problems
Timed Up & Go test ; chronic organ failure
NYha functional assessment
follow-up

ventricular ejection ; acute heart failure ; precapillary pulmonary hypertension
aortic valve insufficiency ; left ventricular assist device implantation
ejection fraction ; cardiac resynchronization therapy ; mild heart failure
functional capacity ; mt
hFPEF ; sodium restriction ; ventricular ; vascular stiffness
magnetically Levitated left ventricular Assist system ; Treating Advanced HF
CHF atrial explants ; sham explants
chronic heart failure ;CHf ; sympathetic tone ; autonomic imbalance
Heart failure ; mortaliteit ; Western society ; cardiovascular diseases
extracorporeal membrane oxygenation ; bridge to recovery ; infarction-related refractory right heart failure
echocardiographic ; invasive hemodynamic
cardiac catheterization ; thrombotic obstruction ; right coronary artery
California office of Statewide healthplanning and Development Patient Discharge
Fontan failure ; systolic ventricular function ; liver disease
HF
pacing-induced dilated cardiomyopathy
mechanistic insight ; electromechanical delay ; dyssynchronous heart failure
trastuzumab ; cardiac comorbidities

economic impact ; AF ; heart failure ; QuÃ©bec ; Canada
cardiac Mena deletion ; cardiac dysfunction ; hypertrophy
bundle-branch block ;LBbb ; non-LBbb
protein levels ; Western blot ; DNA fragmentation ; tunel ; autopsy samples
Chinese herbal medicine ; adjunctive treatment ; dilated cardiomyopathy ; heart failure
implantable cardioverter-defibrillator deactivation
EH ; CH ; cardiac filling pressures
right atrium mass ; prolapse ; tricuspid valve ; stenotic
cutoff level ; NT-probNP
heart failure ; protein kinase
HF
Seattle Heart Failure
dopamine ; nesiritide strategy
nitrite
neurological ; cardiovascular
cox regression ; cardiovascular events ; psoriasis
cPG ; HF
no production ; flow-mediated dilatation ; et
aHF
systolic function
BETs ; mouse TAC model ; human HF

cardiac nurses

transfusion thresholds ; mortality
Czech Republic
MADit-cRT ; device

UM/VA ; va-RT
heart failure
Western blots ; monoclonal antibodies ; Ser83 phosphorylation ;HF
serum albumin ; left ventricular assist device implantation
New York Heart association
functional MS ; ring annuloplasty ; ischemic MR ; LV dilatation
Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure patients
pathophysiology ; HF
ED physicians ; New Jersey ; New York
psoriasis patients ; smoked ; diastolic blood pressure ; body mass index
Exercise intolerance ; heart failure
echocardiography ; shunt implantation
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
cox models ; ST2
TM interventions ; sTS
HRQoL
NT-probNP ; circulation ; HF patients
energy metabolism ; heart failure ; hypertrophied heart
MS ; LV dilatation ; functional MS
PAD ; ankle-brachial index
HR ; ivabradine ; TAC ; Ea
mechanical cardiac support ; renal function
ecmo ; VAD ; ecmo+VAD
mortality ; morbidity ; cancers ; budget
anticoagulation ; heart disease ; rate control
inotropic effect ; beta blockers ; heart failure
interleukin receptor family member ; ST2 ; beta-blocker therapy ; chronic heart failure
heart failure ; systolic heart failure
rhythm-control ; rate-control
hemoglobin levels
Functional MS
HF epidemiology ; health service provision ; HF ; LA
Heart failure ;HF
heart failure ;HF
CF lVAD ; AI ; heart failure
anemia ; heart disease
left ventricular dilatation
ventricular assist devices ; device therapies
device
renal dysfunction ; mechanical cardiac support
HF cohort
computing readmissions ; hospital rankings
cfa
pb ; patients ; HF ; centrale pattern generator
nontreatment
serum factors ; markers voor coagulability
iCD

bNP ; NT-probNP ; biomarkers ; heart failure
Cardiorespiratory fitness ; body mass index ; heart failure mortality ; Cooper Center Longitudinal Study
pro-adrenomedullin ;MR-proADm ; fFM
diet ; exercise ; attention control
Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
implantable cardiac defibrillator
ATP demand ; XO-mediated ROS ; mitochondrial respiration ; contractile function
physical activity ; cardiovascular ; diabetes mellitus ; hypertension ; hyperlipidaemia
systolic HF ; unclear etiology ; coronary angiography
Atrial fibrillation ; congestive heart failure ; rhythm-control ; rate-control strategies
ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
circulating fragments ; n-terminal pro-b-type natriuretic peptides ; plasma ; heart failure patients
heart failure ;HF ; left ventricular ejection fraction ;HFpEF
heart failure ; implantation ; ventricular assist device
HF ; cardiac murmurs ; blood pressure ; hg
adenylyl cyclase ; g-protein coupling
HF ; spontaneous VT ; beat-to-beat QT intervals
biventricular dysfunction ; isolated HeartMate II
tug test ; COPd ; CHF ; cRF
pressure-overload-induced heart failure
Nursing ; social mandate ; nursing care
hemodynamically unstable ; cPR
isoproterenol ; cXL-1020 ; myocytes ; hearts
b treatment ; cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
heart failure ; ventricular tachycardia
Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
Exercise intolerance ; chronic HFPEF ;QOL
energy substrate metabolism ; working hearts ; aac
SCHfi
CAD ; severe CAD
diabetes mellitus ; cardiovascular disease
CVd ; psoriasis
haemodynamic ; pulmonary
prediction rule
Rotterdam ; psoriasis ; cardiovascular outcomes
HR ; tNF ; nbDMARD
aCS procedures ; MT ; VAD
hospital ; cardiac specialty hospital ; South dakota
medical records
ecmo group ; egFR ; egFR
trastuzumab-related CHF
acute HF
biomarker-guided clinical
hospitals

cardiac death
HF-related cachexia ; RV function ; body composition
hospital mortality
rehospitalization
cognitive impairment ; mortaliteit
sonographic ; histological ; functional abnormalities
natriuretic peptide ; biomarkers
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
Spironolactone ; hyperkalemia ; kidney injury
bNP ;PAD ; bNP ; HF
sympathetic ; parasympathetic activity ; HF
eh ; systolic blood pressure ; renal impairment ; hypertension
exercise training ; ambulatory HF
mouse HF model ; compensated LV hypertrophy ; HF ; hHD
left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
heart transplantations ;LV assist device implantations ; heart failure admissions
chronic myocardial ischemia ; heart failure
HFpEF
mechanical cardiac support ; renal function ; heart failure
Surgical revascularization
base hgb ; exercise training ; kccQ
Morpholino-based knockdown ; nucleolin ; protein expression
CAD ; systolic HF
techniek ; sternotomy ; cardiopulmonary bypass
MS ; HF ; functional MS ; medical treatment
parasympathetic function ; HF evolution
aggressive medical treatment ;HF ; HF ; MS
jugular venous pressure ; peripheral oedema
Heart failure ;HF
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
Fontan circulation ; sVR index ; cardiac index
isolated lVAD ; patients
mineralocorticoid receptor antagonists ; race
hereditary ; congenital abnormalities ; heart ; nontraumatic death
Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
isolated HeartMate II lVAD

health insurance ; health system ; u.s. Food and Drug Administration
cutoff value ; NT-probNP testing ; ED patients ; acute heart failure
blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status ; whites
albumin ; lVAD ; postoperative survival
Cytoscape ; functional enrichment analysis ; DAVID
cardiovascular conditions ; HF
patient safety
HF-induced remodeling
right heart circulation ; right heart failure
Raf-MEK1/2-erk1/2
MI ; HF
bisphosphonate ; heart failure
kosten
sustainability

Xanthine oxidase inhibition ; ventricular systolic ; diastolic function ; cardiac volume overload
heart failure ; preserved ejection fraction ; doppler echocardiography
heart failure ;HF ; Heart Failure adherence ; retention trial ;HARt
HF ; preserved ejection fraction ;HFpEF ; hypertension
NYha functional class ; quality-of-life score
Myocardial infarction ; left anterior descending coronary artery occlusion
HFpEF ; breathlessness ; fatigue ; fluid retention
immunodetection ; NT-probNP ; antibodies
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
Î²-Blockade ; cardiac angiogenesis ; heart failure ; VEGF signaling pathway
myocardial ischemic events ; cardiac resynchronization therapy
aortic valve surgery ; post- lVAD AI
unloading ; heart ; isolated HR reduction ; systolic heart failure
spironolactone ; systolic heart failure
Heart failure ; adult medicine ; atheromatous coronary disease
Heart failure ;HF ; Latin America ;LA ; HF
rehospitalization ; medicare ; fee-for-service
HF ; cRT ;hazard ratio
palliative
diagnosti test ; HFpEF
oxidative stress ; GTPase Rac1 ; hearts ; ANS mice
circulating mediator ; insulin resistance ; monocytes ; inflammatory stimul
cardiovascular death ; urgent cardiac transplant ; death
medications ; outpatients ; heart failure ; NCDR PINNACLE
nonselective ; selective beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure


Intravenous iron ; heart failure ; iron deficiency
heart failure ; Emergency Department ;ED ; ED
stress conditions ; significant ; remodelling ; heart failure
non-ischemic ; ischemic heart failure
psoriasis ; systemic ;UV
RV dysfunction ; weight loss ; abnormal body composition ;HF
HR

diastolic dysfunction ; hFPEF
Î²-Adrenergic receptor blockade ; heart failure ;HF
right ventricle overload ; stroke volume ; left ventricular ejection time ; lVET
NT-probNP ; HF patient plasma ; immunoprecipitation ; mass spectrometric analysis
Chromatin-associated proteins ; chromatin ; DNA ; gene expression profile
PD ; therapy ;HF
pulmonary hypertension ;PH ; heart failure
robot-assisted gait therapy ; LokomatÂ® system ; heart failure patients
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
ET ; HDL function ; ET ; CHF-NYha-IIIb ; HDL function
Cardiac failure ; diabetes ; molecular mechanism ; diabetes ; heart failure
exertion ; therapeutic ; exercise ; hemodynamic status
lVET ; death ;ICU
congestive heart failure
aIM ; implantable cardioverter-defibrillator deactivation
mitochondrial structure ; sarcomeric microstructure
heart failure ; ejection fraction
gut ; inflammation ; dietary interventions ; heart failure ; heart failure
pPR ; acr ; CMS
LCx ; LAD ; two-vessel disease
CHF ; emergency department ;ED ; intubated
CHF ; activated neurohormonal systems
zSF1 rats ; heart failure ; ejection fraction
physician follow-up ; discharge ; death ; readmission ; heart failure
heart magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia
arterial tonometry ; lVET ; precapillary PH ; heart failure
Cross-talk between the heart ; adipose tissue ; cachectic heart failure ; body composition
line ; mutant mice ; overexpressing hand2 ; heart muscle cells
transoesophageal echocardiography ; patent ; thrombosis ; migration
heart rate ; renal function ; spironolactone
dialysis patients ; echocardiographic
microRNAs ;miRNAs ; heart failure
paradigm-HF ; paradigm shift ; chronic heart failure ; Chronic heart failure ; cardiology
consenting ambulatory HF patients ; left ventricular ejection fraction
New Zealand White rabbits ; renal DNx ; CHF
QT variability ;Qt ; repolarization lability ; QTV ; cardiac death
Beta-blocker dose ; resting ; HR
mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
cardiovascular disease
POc technology
psoriasis ; cardiovascular disease ;CVd
hospital Compare ; AMI mortality
readmissions
proteins ; acid
Rhythm control therapy
e-septal

cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
diastolic dysfunction ; filling pressures ; doppler echocardiography
Cardiac magnetic resonance postcontrast ; heart failure ; ejection fraction
Myocardial collagen ; collagen cross-linking ; titin isoforms ; phosphorylation
RAS-blocker uptitration ; hFrEF ; HFpEF
Hemoglobin ; exercise ; health status ; chronic heart failure ; HF-acTION
systems proteomics ; cardiac chromatin ; nucleolin ; cellular plasticity ; cardiomyocytes
Plasma samples ; HF patients
cardiomyocytes ; norepinephrine-induced hypertrophic responses
heart failure ; CLcnka sNP
GDMT ;control group ; GDMT ; BAT ;treatment group
HR
transduction pathways ; proteins
alendronate ; alendronate ; heart failure
cardiovascular disease ; dRS deciles
index admission

beta-blocker therapy
heart failure ; bisphosphonates
frailty ; risk ; heart failure ;HF
miRNAs ; cardiac remodeling ; heart failure
early medical management ;HF
diastolic dysfunction
sandwich AlphaLISa ; immunoassays ; NT-probNP
symptomatic adult Fontan ;SAF
death ; biological phenotype ; deficit index
sinus rhythm ; antiplatelet agents ; anticoagulants
implantable cardioverter-defibrillator deactivation
heart failure ; left ventricular ;LV ; ejection fraction
cardiotoxiciteit ; doxorubicin ; anti-neoplastic agent ; cancers
aCS ; oHT ; transplant ; MT ; VAD
natriuretic peptides
RAS- ; Î²-blocker dose
Î²-Blocker-induced enhancement ; cardiac angiogenesis ; therapy ; cardiac function
HF ; rheumatoid arthritis ;RA
Bax ; bcl-2 proteins
hospital rates ; HF patients ; CMS
feeding ; nutritional strategies ; anti-inflammatory effects ; CHF
drugs ;HF ; ejection fraction ;HFrEF
hyperkalemia ; acute kidney injury ; spironolactone
Renal denervation ; dnx ; CHF
MT ; VAD groups ; aCS
refractory congestive heart failure ; peritoneal dialysis
Mammalian enabled ; mena ; cytoskeletal actin dynamics ; heart failure ;HF
heart failure ; elevated left atrial pressure
Heart failure ; preserved ejection fraction ; hFPEF ; cardiovascular reserve
diastolic dysfunction ; hFPEF
physician follow-up ; discharge ; physician continuity ; heart failure
ambulatory iCD patients ; mortality
ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
Gastrointestinal bleeding ; ventricular assist devices
nicorandil ; cytotoxic effect ; doxorubicin ; ehrlich carcinoma
Myxomas ; cardiac benign tumors ; left atrium
fes ; preserved ejection fraction ;HFpEF
bNP ; NT-probNP ; coronary artery disease ;CAD

circulating forms ; NT-probNP
ecCT
aerobic capacity ; left-hand grip ; body weight ; waist circumference ; anxiety
Process redesign contextual framework
Myocardial loss ; iRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
Functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation ;MR
lVET ;ICU admission ; precapillary PH ; heart failure
heart failure-related hospitalization ; death ; left ventricular ejection fraction
Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbidity
tissue ; doppler imaging ; left ventricular filling pressure ; systolic heart failure
lean ; zSF1 group ; obese ; zSF1 groups ; hypertensive ; diabetic
heart failure ; preserved ejection fraction ; hFPEF
Kansas City Cardiomyopathy Questionnaire ; heart failure ; ejection fraction
activating myocardial pde2 ; intracellular antiadrenergic therapeutic strategy ;HF
spironolactone ; medications
HF hospitalization
IE ; heart failure ;HF ; death ; cRT-d
pharmacologic treatment
Mechanical dyssynchrony ; QRs complex ; cRT
coronary occlusion ; stent occlusion
carotid intima-media ; psoriasis
transfusions ; heart disease
exercise ; diet ; VO2 ;joint effect
PVf ; pb ; pb ; BP
chronic heart failure ; Hungary
RV dysfunction ; cardiac cachexia
Remote monitoring ;RM ; heart failure
eCG parameters ; cRT
sst2 ; BB ; cardiovascular event
breast cancer patients ; trastuzumb-related CHF
HF ; EMd ; dyssynchronous failing heart
acute heart failure ; aHF ; heart failure ;HF
angiogenesis ; post-myocardial infarction ; heart ; heart failure
aldosterone antagonist ; heart failure
surgery ; HF ; hypertension ; vasodilators ; diuretics
Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
HR ; beta-blocker
pde2 ; hearts ; Î²-AR stimulation
psoriasis ; disease ; atherosclerosis ; cardiovascular events ; psoriasis
anemic ; iron-deficient adult patients ; heart disease
heart failure ; hospitalisation
egFR ; diuretics ; uncontrolled hypertension ; ESRD
trastuzumab ; CHF ; nontrastuzumab
EO-cFUs ; mortality
Point-of-care systems ; NP ; ED ; community outpatient settings ; acute heart failure
heart failure ; ejection fraction ; myocardial infarction
lVAS
black race ; HF hospitalization ;HR ; cardiovascular mortality
exercise ; cardiac disease ; heart failure
HFPEF
physician adherence ; HF cPGs
HF risk factors ; fit men ; HF mortality ; unfit men
HDL function ; CHF ; et ; HDL-mediated vascular effects
coronary artery disease ; systolic heart failure
Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic
Ea ; total arterial compliance ;TAC ; end-systolic elastance ; ees
Biventricular support ; HeartMate II lVAD ; CentriMag rVAD
Renal dysfunction ; myocardial infarction ; coronary artery bypass grafting ;CABG
cardiovascular risk factors ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
isoprenaline infusion ; SDQT ; hNorm ; HF
Renal dysfunction ; cardiovascular events ; caBG
Pyridostigmine ; vascular endothelial growth factor ; protein ; left ventricle ; myocardial angiogenesis
egFR ; VAD group ; ecmo+VAD group ; ecmo group
CHF ; international Classification of Diseases ; Ninth revision
RV dysfunction ; lower body mass index ; fat mass index ; cachexia
cRF ; HF mortality risk ; men ; HF risk factors
Robot-assisted gait therapy ; LokomatÂ® system ; heart failure patients
cardiac growth ; plasticiteit ; disease recapitulates ; chromatin remodeling
idiopathic dilated cardiomyopathy cohort
dopamine ; nesiritide
medline ; EMBAse ; cochrane databases ; clinical trial registries
chart review
HF ; HF
Ea ; TAC ; HR ; ees
Care management ; content-driven telehealth technology ; Medicare
ERC ; pure epicatechin ; muscle function
biomedical reasons ; nonprescribing
myocardium displays ; pka subunits ; downstream signaling
atrial fibrillation ; carvedilol ; metoprolol
heart failure patients ; implantable cardioverter-defibrillator
functional MS ; valve plasty ; degenerative MR ; LV
HeartMate II insertion ; HeartMate II implantation
management ; end stage heart failure ; Heart failure ; public health ; europa ; north America
MIs ; Killip class
heart failure ; mechanical support devices ; Cardiology-cardiovascular Surgery Consensus report ; Heart failure
elastic n2 bus segment ; PEvk segment
Self-care of Heart Failure index ; schfi
proteomics ; chromatin-associated proteins ; detergent ; disease
HeartMate ; left ventricular assist system ; lVAS ; advanced heart failure
Nicorandil ; mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats ; mechanism of cardioprotection
pharmacologic management ; acute HF ; chronic HF
arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
cXL-1020 ; hno ; inactive cXL-1051
tNF antagonists ; HF hospital admissions ; nbDMARDs ; RA
ejection fraction
gLS ;HR ; CV
exercise ; diet
mortality
nurses ; magnet
physician adherence ; class I recommendations
HF ; drug treatment ; PAF biosynthetic enzymes ; lyso-paf-AT
myocardial infarction ;MI ; heart failure ;HF
cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments
Heart rate reduction ; exercise performance ; heart failure ; ejection fraction ; beta-blocker
RAS ; hypertension ; nephropathy ; congestive heart failure
serum levels ; brain natriuretic peptide ; bNP ; creatinine ; natremia
mADIt-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy ; nCT
NT-probNP ; MR-proANp ; MR-proadm
isoelectric focusing ; RIÎ± ; ser77 ; ser83 ; vivo phosphorylation sites
SDQT ; SD ; RR intervals ;SDRR ; index ; QTV ; heart rate variability
e/eseptal ; e/emean ; s'septal ; QRs width
Logistic regression models
IVc occlusion ; co correlated ; twist ; apical rotation ; RS ; RS synchrony ; CS
congestive heart failure ; United States
diuretics ; morbiditeit ; mortality
heart failure ; follow-up
devices ; gastrointestinal bleeding
cardiac events
egFR ; VAD group ; ecmo+VAD group ; renal function
sst2/low-dose BB ; sst2/high-dose BB
CHF ; ED visits ; CHF patients intubated
HF ; noncardiologist physicians
zebrafish ; nucleolin ; genomic reprogramming
LV ejection fraction ; pcWP
HF ; AMI ; mortality
emergency department ; acute heart failure ; Collins
cardiopulmonary exercise ; quality of life score ; muscular strength ; quadriceps force
public health ; air pollution ; industrial areas ; cardiovascular health
eCG ; congenital accessory pathways ; ion channelopathies ; cardiomyopathy
idiopathic dilated cardiomyopathy ; tuscany
HF ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
Morbiditeit ; mortality ;HFpEF ; HF ; EF
HF ;heart failure ; t2d ;Type 2 diabetes ; Skm ;skeletal muscle
heart failure ;HF ; inpatient ; outpatient models
molecular biomarkers ; pathophysiology ; chronic HF
carvedilol ; metoprolol ; heart failure patients ; devices
erythropoiesis-stimulating agents ; anemia ; heart disease
intravenous iron ; exercise tolerance ; heart failure
mitral valve plasty ; degenerative mitral regurgitation
in-trial resource utilization ; unit costs ; QuÃ©bec Health Insurance Board ; kosten ; Ontario Case costing Initiative
knockdown ; BET bromodomain-containing protein 4 ;brd4) ; cardiac tissues
Dual RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction ; treatment
follow-up visits
heart failure ; pediatric mechanical cardiac
economic models ; lVAD
echocardiographic score ; cRT response
ejection fraction
AF ablation
If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; preserved ejection fraction
tidal respiration ; gadolinium-chelate contrast agent
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
Medicare inpatient ; HF admissions ; acute care hospitals ; United States
catheter ablation ; atrial fibrillation ; heart failure ; preserved ejection fraction
dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; rose acute heart failure
DAPc ;dystrophin-associated protein complex ; sarcomeric microstructure
mouse ;HF model ; hHD ; salt loading ; uninephrectomy ; ANG II infusion
HF ; preserved ejection fraction ; pEF ; uptitration
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat metabolic risk
echocardiographic ; response ; cardiac resynchronization therapy ; cRT
serum creatinine level ; serum potassium level
chromatin subproteomes ; heart failure ; proteins ; chromatin structure
Hum-retn mice ; cardiac mRNA ; inflammatory ; cell adhesion genes ; Retn
anemia ; chronic heart failure ;HF
University of Connecticut Heart Failure Center ; cardiologist ; heart failure
circulating NT-probNP ; antibodies ; nonglycosylated ; nonterminal epitopes
RV failure ; diagnosti procedures ; management ; intrinsic left ventricular dysfunction
PD ; weight loss ; diuretic response ; peripheral edema
Chronic heart failure ; transforming growth factor ; atrial
HFpEF ; ccq
HeartMate II lVAD ; CentriMag rVAD
voordelen ; cardiovascular ; heart failure
HF ; MI ; preserved ; reduced ejection fraction ;EF
inpatient admissions ; hospital days ; emergency department ;ED
nbDMARD ; tNF antagonist
trastuzumab ; cardiotoxiciteit ; congestive heart failure ;CHf
pyridostigmine ; methylatropine ; propranolol ; cardiac sympathovagal balance
uPR effectors ; protein kinase ; r-like ER kinase ;perk ; calreticulin ; CHOp ; HF tissues
myosin binding ; protein-c phosphorylation ; ser23/24 troponin I phosphorylation ; HF
echocardiographic ; natriuretic peptide ; inflammatory markers
Phosphodiesterase-2 ; failing hearts ; blunts beta-adrenergic responses ; cardiomyocytes
carvedilol ; thromboembolic events ; heart failure ; Î²2-receptor haplotype
hFrEF ; exercise performance ; resting ; HR ; beta-blocker therapy
paf ; metabolic enzymes ; heart failure
XO inhibition ; cardiomyocyte bioenergetics ; LV function ; chronic aCF ; rat
RCts
cox hazard models ; ESRD ; to death ; ESRD ; death ; ESRD
renal dysfunction ; stroke ; myocardial infarction ; heart failure ; caBG
heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold ;AT
heart failure ; heart failure nurses ; follow-up ; cardiology services
HF rats ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
recreational athletes ; sudden cardiac deaths ; males ; atherosclerotic CAD
rheumatic ; MS
womens Health Initiative ; HF hospitalization
CHF-developed infarcted animals ; left ventricle end-diastolic pressure
RV ; pathophysiologic mechanisms ; RV dysfunction
dialysis-dependent patients ; HF ; cRT implantation
Peak oxygen consumption ; oxygen pulse
economic climate ; NHs ; behavioural-change ; chronic disease ; exercise programmes
post-hCT CHF ; hCT ; City of Hope

pigs ; cava ; icc ; snared ; co
doxorubicin ; ip ; serum resistin levels ; Hum-retn mice
kosten ; high-volume physicians
CHF ; carbohydrates
deactivation
aldosterone receptor antagonists ; morbiditeit ; mortality ; systolic heart failure
scn5a transcript ; uPR ; cardiac genes ; HF
east ; rhythm control therapy ; AF ; cardiovascular complications ; AF
albumin levels ; nutrition ; inflammation ; hepatic function ; lVAD implantation
Right ventricular ;RV ; left ventricular assist device ; lVAD
pasp ; pasp
cox proportional hazards
lipolysis ; energie expenditure ; natriuretic peptides ;NPs ; CC
non-fatal stroke ; hospitalisations ; heart failure
hearts ; mena ; cardiac injury ; mena ; HF pathophysiology
biomarkers ; molecular dysfunction ; chronic HF
ST2 ; reclassification ; risk ; c statistic ; net reclassification ; discrimination
gls ; index beat method ; CV events ; cox proportional hazards analyses
non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
VAD group ; ecmo+VAD group ; ecmo group
Ambient air pollution ; cardiovascular health ; acute myocardial infarction
ccq ; kaplan-meier curves ; death ; hospitalization
RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
Testosterone therapy ; exercise rehabilitation ; chronic heart failure ; testosterone status
pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone
AMI ; heart failure ; kidney infection ;UTI
proteomics ; pathway analysis ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural
IC ; multicenter Automatic Defibrillator Implantation trial-Cardiac resynchronization Therapy
Olmsted County ; Minnesota ; MI diagnosed ; HF
Health Buddy Program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
HF
odds ratio ;hazard ratio ; death ;HF ; AMI admission
neurohumoral blockers ; HF hospitalization ; co-morbidity burden
left ventricular ejection fraction ; heart failure ; Heart Failure Survey ; israel
vascular endothelial growth factor ;veGF ; compensatory hypertrophy ; cardiac failure
CAD ; CAD
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
apoptosis ; heart failure
diagnose ; alternatieve treatments
diuretic efficacy ; neurohormonal activation
uPR ; na+ channel mRNA splice ; cardiac ; na+ current ; human HF
LVEF ; LVEF
lVAD ; transplantation ; budget
bets ; transcriptional pause release ; transcription ; pathological stress
eCG ; atherosclerotic CAD ; sudden cardiac death
HF ; index AMI ; hazard ratio
cRT-d ; IE ; defibrillator-only therapy ;HR
HR dynamics ; HR variabiliteit ; risk stratification
cardiopulmonary exercise ; echocardiographic assessment ; myocardial function ; left ventricular filling
speckle tracking echocardiography ; ste ; BiVP ; right ventricular pressure overload ;RVPO
atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
percutaneous coronary revascularization ; hemodynamically
diabetes mellitus ; metabolic risk factors ; heart failure ; preserved ejection fraction
sex ; EF ; bNP ; HF ; bNP ; sex ; EF
perk inhibition ; scn5a ; kv4.3 mRNA levels ; na+ channel mRNA splice
LVEF ; long-term mortality ; hospitalization ; acute decompensated HF
Mena expression ; HF ; mena ; cardiac pathophysiology
salt loading ; uninephrectomy ; ANG II infusion mouse model ; cardiac function ; mice ; HF
echocardiographic score ; LV reverse remodeling
atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
HR reduction
bottleneck stent ; myocardial infarction ; antiplatelet medication
ANS mice ; LV ; lung weight
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
Trastuzumab ; CHF ; nontrastuzumab users ;hazard ratio ;HR
systolic heart failure ; spironolactone
Rad variant ;Q66p ; congestive heart failure ; humans
functional enrichment analysis ; programmed cell death
atrial fibrillation ; Atrial fibrillation ; Stroke prevention trial
etiology ; comorbidities
intestinal morphology ; permeability ; absorption function ; CHF
anaerobic metabolism ; respiratory
ARNI ; cardiovascular mortality ; hospitalization ; heart failure
myocardial DD ; muscle strip stiffness ; titin hypophosphorylation
quadriceps force
proteins ; cardiac hypertrophy ; nucleolin
idiopathic dilated cardiomyopathy
high-volume physicians ; readmission rates
NP measurement ; POc measurement ;NPs
benefits ; follow-up
Kansas City Cardiomyopathy Questionnaire ; kccq ; HF ; EF ; HFpEF
tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; index ; right ventricular contractile
biventricular support ; hybrid system ; HeartMate II lVAD ; CentriMag right ventricular assist device ; rVAD
Blood pressure ; arm cuff ; stroke volume ;SV ; ejection fraction ; end-diastolic volume ; echocardiography
fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue histologic analysis
Caucasian ; genotyped ; sNP rs10927887 ; ka renal chloride channel gene ;CLcnka
exercise training ;HF patients ; exercise training therapy
contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
NT-probNP ; plasma ; dyspnea ; left ventricular dysfunction ; ED
heart ; cardiac hypertrophy ; HF ; death ; fibrosis ; inflammation
HF-acTION cohort ; hgb ; baseline HRQoL ; kccq
circulating progenitor cells ; c pcs ; endothelial repair ; cardiovascular
right ventricular ;RV ; body composition ; advanced heart failure ;HF
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function
American college of Cardiology ;American Heart association ; RAS
functional MS ; valve plasty ; degenerative MR ; LV
EO-cFUs ; cd34+vegFR2 ; cells ; nondiabetic patients
implantable cardioverter-defibrillator deactivation ; heart failure patients
functional MS ; valve plasty ; annular size reduction ; degenerative MR ; LV
frailty ; heart failure ;HF
LV remodeling ; diastolic properties ; XO inhibition ; heart failure
SDQT ; HFVT ; HFVT ; hNorm group ; fixed-rate atrial pacing
borderline ; female ; preserved
t1-mapping techniek ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
bNP ; inhospital mortality
IEs ; cRT-d recipients ; heart failure ; death
expenditure ; health per capita ; gross national income per capita ; HF ; la
bt ; DT ; bt
AF ; pharmaceuticals ; hFPEF
blood pressure control ; lipid-lowering therapy ; smoking cessation ;RAS
virtual cohorts
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
implantable cardioverter-defibrillators ; iccs ; cardiac resynchronization therapy ; cRT
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
Low-sodium DASh diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
HFpEF ; echo-doppler cardiography ; invasive haemodynamic assessment
RAS- ; Î²-blocker uptitrations ; hFrEF ; HFpEF
pasp ; pasp
skeletal muscle sarcomere structure ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
Physician volume ; medically managed diseases ; HF
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
eplerenone ; HF-ref ; hyperkalemia ; wRF
mitochondrial complex ; aac ; phosphocreatine ; ATP
sst2/low-dose BB ; sst2/high-dose BB ; cardiovascular events
frail ; intermediate frail
QRs morphology ; cardiac resynchronization therapy ; cRT
hFPEF ; cardiac event
RM ; discharged ; heart failure
acute heart failure ; aHF
embryonic gene programs ; pathological heart disease ; transcription factors ; gene programs
mDC
LBb ; implantable cardioverter defibrillator-cRT
isolated heart rate ;HR ; ivabradine ; systolic heart failure
cardiovascular death ; stroke ; heart failure ; myocardial infarction
heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; heart failure
Cardiac-resynchronization therapy ; cRT ; chronic systolic heart failure ; QRs
perk activation ; scn5a ; Kv4.3 channel mRNAs ; transient receptor potential cation channel m7 ;TRPM7 channel mRNA
implantable cardioverter-defibrillator ; Heart Function Clinic ; university health network ; toronto ; Canada
pasp ; pulmonary hypertension ; ventricular contractile reserve
MI ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ;HF
Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ;coRAL ; stenting ;RAS
mortaliteit ; heart failure ;HF ; implantable cardioverter defibrillators ;icds
left-to-right interatrial shunting ; heart failure ; ejection fraction
Mediterranean and Dietary Approaches to Stop Hypertension ;DASh ; diet scores ; mortaliteit ; postmenopausal women ;HF
multiparametric echocardiographic score ; reverse remodeling ; cRT
Yorkshire swine ; pacemakers ; ventricularly paced ; heart failure
antagonists ; inhibitors ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
HF ; HF ; epidemiology ; SH ; c'd ; rheumatic fever
mortality ; readmissions ; costs
caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; obese older patients ; hFPEF
chronic heart failure ;HF ; hemodynamic disorder ; syndrome
medications ; heart failure ; ejection fraction
HFpEF ; diastolic filling time ; heart rate
mice ; cardiac myocyte-specific Mena overexpression ;TTA ; tgtetMena ; cardiac pathology
antiplatelet agents ; anticoagulants ; vascular diseases
international Right Heart foundation Working Group ; syndrome ; right heart failure
POc systems ; measuring NP levels
lb ; QRs ; cardioverter ; defibrillator-cRT
echocardiography ; cardiac diameters ; cardiac function
electronic databases ; medline ; EMBAse ; PsycINFO
functional capacity

systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke volume index
AF ; severe heart failure ; financiÃ«le burden
follow up body weight ; FM ; fm ; fm ;cc
r. Cluster analysis
left ventricular ejection fraction ; left ventricular diastolic end diameter
eccentric ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
left ventricular ejection fraction ; heart failure ; preserved ejection fraction ;HFpEF
Î²-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
hgb ; kccq scales ; hgb ; exercise training ; HRQoL
heart failure ; hospital discharge ; readmissions
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; index ; preserved cardiac index
myofiber dynamics ; myofiber ; EMd ; dyssynchronous HF
crude ; ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
truncated na+ channels ; unfolded protein response ; uPR ; scn5a electric remodeling ; HF
intermacs ; interagency Registry for Mechanically Assisted circulatory Support
allopurinol ; LV contractile function ; efficiency ; XO-mediated ROS effects ; myofilament
techniek ; systolic function ; HFpEF ; long axis function ; exercise
physicians ; advanced heart failure
concurrent HF ; mortality ; hazard ratio
AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone
receptors ; g-protein-coupled receptor kinase-2
NT-probNP assay ; nonterminal epitopes ; glycosylated
scn5a ; AngII ; hypoxia ; uPR ; na+ current
isolated heart transplant ; ecCT
bNP ; diastolic dysfunction
therapy ; comorbidities
rehospitalization ; Medicare hospital claims ; Medicare ; post-acute care transfer policy
heart failure ; refill compliance ; etidronate ; alendronate
AT ; metabolic exercise ; cardiac ; kidney index score
physical activity ; cRF ; HF mortality
et ; HDL-mediated protective effects ; molecular pathways ; chronic heart failure ;CHf
dopamine ; nesiritide ; renal function
anemia ; iron deficiency ; medline ; cochrane Library
kccq ; interne consistency ; HFpEF ; ronbach
implantable cardioverter defibrillator-cRT ; non-LBbb ; QRs

alendronate ; etidronate- ; raloxifene-treated
chemotherapy ; trastuzumab ; CHF ; international Classification of Diseases ; healthcare common procedure coding system codes
contemporary heart failure ;HF ; therapies ; HF ; left ventricular ejection fraction ;LVEF
hART ; HFpEF ; HF met reduced ejection fraction ;HFrEF
conscious dogs ; tachypacing-induced HF ; cXL-1020 ; contractility ; elastance ; venoarterial dilation
bone morphogenetic protein ; rRNA transcription ; heterochromatic chromatin
actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
resistin ; anthracycline-induced cardiotoxiciteit ; heart failure ; macrophages
extracellular matrix ; left ventricular biopsies ; tissueFAXs technology
systolic HF ; Danish Heart Failure database ; ESRD ; Danish Registry on Dialysis
left ventricular assist devices ; lVADs ; advanced heart failure ; pump dysfunction ; pump replacement
ST2 ; amino-terminal pro-b-type natriuretic peptide
Biventricular pacing ;BiVP ; cardiac output ;co ; cardiac surgery
fully magnetically levitated lVAS ; Seattle Heart Failure
New York Heart association ;NYha ; chronic heart failure ; reduced ejection fraction ; Canadian special access programme
AlphaLISa immunoassays ; antibodies ; termini ; circulating NT-probNP
creatinine ; bNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
mistargeting ; altered regulation ; Rad Q66p ; rGK protein ; efficacy in vivo
Myocyte hypertrophy antecedent to heart failure ; gene expression ; DNA
hospitals
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure ; PubMed
sst2/high-dose BB ; sst2 ; BB ; cardiovascular event
neurohormones ; adipokines ;cc ; fat free mass ; fm ; fat mass ;FM
cardiac plasma membrane ; s1PR1 ; Î²1AR overstimulation ; heart failure
Sprague- dawley rats ; sham ; aCF ; allopurinol
myocardial collagen ; myocardial delayed enhancement imaging
saxagliptin ; sitagliptin ; follow-up
Catheter ablation ; AF ; compensated HFPEF ; left ventricular ;LV ; ejection fraction
BB therapy ; sst2 measurement ; chronic heart failure ; BB
cRT ; control group ; hazard ratio
ESRD ; systolic HF ; eGFR
pasp ; length-force relationship ; RV function evaluation ; LV dysfunction
tunel assay ; apoptotic cells ; tunel-positive cells
pure Hno donor ; myocardial function ; HF
biventricular support ; rVADs ; explanted
congestive heart failure ; Midwestern state ; South dakota
cardiomyocytes ; mechanical ; humoral stimuli ; myocardium
mt
cox proportional hazards ; transplantation ; LV assist device implantation ; heart failure hospitalization
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase
intraclass correlation coefficient ; icc ; kappa coefficient ; md
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
race ; exercise training ; chronic heart failure ; Heart Failure ; trial Investigating Outcomes in Exercise TraiNing ;HF-acTION
Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
heart failure ; preserved ejection fraction ; hFPEF ; heart failure ; overweight ; obese
Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
Renal dysfunction ; heart failure ;HF ; renal disease ; eRD
echocardiographic score ; LV reverse remodeling ; LV end-systolic volume
Peripheral artery disease ;PAD ; heart failure ;HF ;HF ; HF ;PAD
heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
peripheral muscle pump ; cardiac filling ; subpulmonary ventricle ; Fontan circulation
biological phenotype ; deficit index ; medical records
SDQT ; HFVT ; hNorm ; Î²-adrenoceptor blockade ; esmolol
Cardiology practices ; national Cardiovascular Disease Registry ; practice Innovation ; Clinical Excellence registry
sts HH ; TM ; medical support ; all-cause mortality ; discharged patients ; heart failure
myocardial infarction ; heart failure ; bisoprolol ; vehicle
in-patient follow-up ; health
CHF ; cardiac explant
tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; CHF-inv
hno donor ; cXL-1020 ; isolated myoctyes ; intact hearts ; heart failure ;HF

MS ; subvalvular ; dynamic ; MS
race ; chronic heart failure ;HF ; exercise training response
histological analysis ; capillary ; coronary perfusion ; ad-flk rats
physician volume ; mortaliteit ; internists ; cardiologists
shuttle walk test ; body mass ; hand grip strength
POc testing ; NP ; ED
heart failure ; CHAr programme ;Candesartan in Heart Failure assessment ; Mortality ; Morbidity
Troponin t ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis
left-to-right interatrial shunting ; patients met heart failure ; ejection fraction
bmi ; weight ; heart rate ; rhythm ; lying ; standing blood pressure ; auscultation ; valvular disease ; pulmonary congestion
myocardial extracellular matrix ; cardiac magnetic resonance t1 mapping ; pathobiology
aldosterone antagonist therapy ; chronic advanced heart failure patients ; post-myocardial infarction ; heart failure patients ; ejection
Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin cardiotoxiciteit
heart failure ; left ventricular ejection ; spironolactone ; Kaiser Permanente Northern California
renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass grafting
septum ;systolic ; thickness ; LV posterior wall thickness ; LV internal diameter ; metoprolol
American college of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
obese older patients ; hFPEF ; caloric restriction ; aerobic exercise training ; VO2
economic analysis ; Patient management Interventions ; Heart Failure ; kosten-effectiveness ; disease management ; heart failure
HF registry ; HF ; EF ;EF ; HFpEF ;EF
BAT ; n-terminal pro-brain natriuretic peptide ; HF
HR variability ; mortality ; AMI ; CHF ;LV dysfunction
exercise ; cell senescence ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
cardiac transplant ; ect ; transplant pool ; donors ; recipients
asymptomatic pediatric Fontan ;PF ; catheterization
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
Lancet ; Anoop Shah ; air pollution ; heart failure ; morbiditeit ; mortality
anemia ; HF ; health-related quality of life ;HRQoL ; HF
cell therapy ; chronic heart failure ;CHf ; disease ; explant-derived progenitor cells
mRI-based models ; dyssynchronous nonfailing ; HF ; canine electromechanics
acute RV failure ; chronic pulmonary arterial hypertension ;PAh ; pulmonary embolism
acute RV failure ; pulmonary embolism ; mortaliteit
serum resistin ; women ; anthracycline-containing chemotherapy ; cardiotoxiciteit
sst2 ; BB ; cardiovascular event rate
Rad Q66p ; cardiomyopathy
ventricular structure ; geometry ; fiber ;sheet orientation ; handling ; slowed conduction
SDQT-to-SDRR ratio ; HFVT ; HFVT ; hNorm
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection
Exercise ; Medical Therapies ; Cardiac Function ; Breath ; Lung congestion
functional electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; left ventricular ejection fraction
tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol ; sympathetic tone
cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs prolongation ; ejection fraction ;EF
fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ; proximal LAD
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
cox regression ; spironolactone ; death ; hyperkalemia ; kidney injury
mortality ;hospitalization ; mortality ; cardiovascular mortality ;HF hospitalization ; cox ; exercise training
neprilysin inhibitors ; natriuretic peptide system ; atrial natriuretic peptide ; natriuretic peptide
TAPse ; pasp ; nonsurvivors ; hFrEF ; HFpEF
HF-acTION ; HF ; ejection fraction ; exercise training
epigenetic ;writer ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac
NT-probNP ; mortaliteit ; acute HF
haematopoietic cell transplantation ; hCT ; congestive heart failure ;CHf ; hCT ; anthracyclines
cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; cumulative administration ; doxorubicin
in vivo inhibition ; mir-25 ; antagomir ; cardiac dysfunction ; murine myocardium ; heart failure
Chinese herbal medicine ;CHm ; dilated cardiomyopathy ; dm ; heart failure
hypertension ; diabetes mellitus ; systolic ; diastolic murmurs
postoperative ; hypoalbuminemia ; albumin concentration
elektrial activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
advanced heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical staff
Baroreflex sensitivity ; time domain ; heart rate variability ;HRv ; CHF-inv group ; sham-inv ; sham levels ; renal DNx
bisphosphonates ; alendronate ; etidronate ; heart failure ; refill compliance
nurse assessment ; cognitive impairment ; hospitalization ; physician ; discharge ; elderly patients hospitalized ; heart failure
carvedilol ; nonselective Î²-blocker ; Î²-blocker metoprolol ; thromboembolic events ; heart failure
cardiac transplant survival ; ecCT
HF ; AMI ; pNA ; mortality
heart failure ;HF ; HF
arrhythmia substrate ;AMI ; HR ; arrhythmia events
doxorubicin-induced cardiotoxiciteit ; Hum-retn ; littermate ; resistin ; retn
hypertension ; compensated HFPEF ; DASh ; srd ; sodium ; kcal
EMd ; dyssynchronous HF
diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular function
ejection fraction ; cardiac index ; inotropes ; inotrope-dependent
hoge-density lipoprotein ;HDL ; endothelial-protective effects ; endothelial cell ; ec ; nitric oxide ;NO
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
degs ; non-ischemic ; ischemic heart failure ; heart failure
insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRs1 ; iRS2 ; insulin-signaling components ; cellular metabolism
admission to discharge ; older adults ; heart failure ;HF ; Nursing Outcomes Classification ;noc
8-fluo-cAMP binding ; wild type ; phosphomimic ; ser77 ; ser83 mutant ; RIÎ± proteins ; double mutant ; wt RIÎ±
preoperative albumin ; lVAD implantation
systolic heart failure ; QRs ; cRT ; hospitalization ; heart failure
cox regression models ; propensity score ; oral glucocorticoid dosage ; HF hospitalisations ; loop diuretics
Functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; chronic heart failure ; systolic function
dialysis patients ; HF
bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke ; Rankin Score
Beta blockers ; readmissions ; heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
dyssynchronous HF ; electromechanical delay ;emd ; myocyte depolarization ; myofiber
QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; ambulatory Heart Failure trial ;RAFt
biomarker studies ; biomarker-guided clinical trial
abnormal liver texture ; nodularity
transplant ; PD ; HF volume management ; post-PD initiation
frailty ; biological phenotype ; weak grip strength ; physical exhaustion
cRT-d ; IE ; IC ; benefit ; cRT-d ; IEs
significant-volume EDs ; discharge patients ; heart failure ; ED ; readmissions ; repeat ED
acute right heart failure ; therapy refractory cardiogenic shock ; heart team ; corporeal membrane oxygenation ; ecmo ; cPR ;ICU
right atrial myxoma ; massive embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
heart disease ; HF ; surgical palliation
heart magnetic resonance imaging ; chelation choices ; heart failure ; arrhythmias
ejection fraction ;EF ; pre-PD ; NYha class IIIb ; right ventricular dysfunction
c pcs ; ecb ; circulating ; cd34 ; vEGFR2 ; cd133+ cells
Gene expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
nitroxyl ; hno ; Angelis salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
continuous-flow lVADs ; heartMate II ;HM II ; HeartWare ; bt ; DT
EF ; EF
skeletal muscle mass ; appendicular lean mass index ; z-score
DASh diet scores ; mortality ; HF ; Mediterranean diet scores
quality of life ; mortaliteit
bNP ; bNP ; inhospital mortality
cardiovascular diseases ; heart failure ;HF ; HF
heart failure ; left ventricular systolic dysfunction ; BB
CLcnka polymorphism ; p. arg83gly ; heart failure ; glomerular filtration rate ; reNAStur cohort
ST2 ; functional capacity ; HF
cardiac VEGF expression ; Akt ; endothelial no synthase activation ; failing hearts
Gene expression profiling ; cultured cardiomyocytes ; jq1 ; drug ; phenylephrine-induced genes
pasp ; right ventricular contractile reserve ; pasp
Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure ; ischemic samples
cardiac insulin-resistance ; aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
post-DASh ; srd brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic
Psychosocial Factors ; Exercise Adherence ; Heart Failure Patients ; Heart Failure ; Exercise Training ;HF-acTION
derivation cohort ; coronary angiography ; systolic HF ; unclear etiology
arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees
rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
angiotensin II ;AngII ; hypoxia ; activators ; abnormal scn5a mRNA splicing ; scn5a variants
HF with reduced ejection fraction ;HFrEF ; treatment ; HF met preserved ejection fraction ;HFpEF
extracorporeal life support ; bridging therapy ; ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional status ; endothelial function ; HFpEF
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
intubation
raloxifene ; mechanism of action ; heart failure
hearts ; tgtetMena ; littermates ; heart mass ; transgenic mice
hFrEF ; exercise protocol ; respiratory gas analysis
drugs ; heart failure ; chart review ; biomedical reasons ; nonprescribing
fat ; lean mass ; fat loss ; catabolism ; adipose tissue ; cardioprotective ; HF
hearts ; fish ; nucleolin ; chamber patterning ; functional deficits ; cardiac looping ; myocyte differentiation
black race ; chronic HF ; exercise performance ; HF hospitalization ; mortality ; exercise training
adverse event rates ; acute myocardial infarction ; congestive heart failure
Macrophages ; cardiomyocytes ; Hum-retn mice ; doxorubicin ; hRetn ;human resistin ; mRNA ; protein expression
lVADs ; CF devices ; HeartMate II devices ; thoratec Corp ; Pleasanton calif ; hVAD devices ; HeartWare intl ; intl ; framingham ; Mass
FM ; plasma NPs ; total adiponectin ; FM ; fFM ; NPs ; adiponectin
sympathetic tone ; parasympathetic tone ; heart rate response ; metoprolol ; atropine
EH ; HFpEF ; HF ; EF ;HFrEF ; hFrEF therapy
plasma collected ; HF patients ; immunoreactive NT-probNP ; NT-probNP
beat-to-beat QT interval ; eCGs ;atrial pacing ; esmolol ; isoprenaline ; atropine infusion

power spectral analysis ; low-frequenncy ;high-frequenncy ;LF ;HF ; CHF-inv ; sham-inv ; sham levels ; DNx
contractility ; ventricular-arterial coupling ; SV
follow-up visits
n-terminal pro-b-type natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
cardiac magnetic resonance ; postcontrast t1 ; hFPEF ; postcontrast t1 ; biomarker ; hFPEF
HF-acTION ; left ventricular ejection fraction ; New York Heart association class II to IV HF
myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic zSF1 rats ; heart failure ; ejection fraction
transcriptional analysis ; cardiac tissue ; mice ; TAC- ; sham-operated ; jq1 ; vehicle ; BET inhibition ; pathological cardiac gene expression programme
cox-proportional hazard models ; negative binomial regression models
systolic blood pressure ; left ventricular ;LV ; hypertrophy ; AT ; AN ; AS ; ANS
hand2 ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene program
cutoff value ; admission NT-probNP ; ED ; acute HF diagnosis
Peak oxygen consumption ;VO2max ; resting ; HR
heart failure ; sudden death ; noncardiac ; cardiac transplant
frailty ; health ABC Short Physical performance Battery ; hABC Battery ; Gill index ; HF
epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; HF progression
CAD ; angiography ; systolic HF
chronotropic response ; heart rate ; follow-up tests ; heart rate
gastrointestinal bleeding ; ventricular tachycardia storm ; terminal heart failure
percutaneous revascularization ; angioplasty ; stenting
HF ; t2d ; ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
HF ; QRs prolongation ; LVEF ; cRT ; reverse remodeling ; LV systolic dysfunction
RV ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure

non-frail ;HR ; frailty ;HR ; Gill index ; HF
HF ; AMI ; odds ratio
Chronic heart failure ;CHf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
Î²-AR stimulation ; catecholamine infusions ; rats ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac Î²-AR responsiveness
chronic PAH ; hospitalized patients ; RV decompensation ; pharmacologic therapies ; RV failure management ; pAH
obese ; zSF1 groups ; heart failure ; ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular DD
Xanthine oxidase ;XO ; rat ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ; acf
free-breathing pulse sequence ; myocardial t1 ; swine model ; tachycardia-induced heart failure
PF cohort ;New York Heart association ;SAF ;PF
medication
physicians ; mortaliteit ; low-volume physicians ; low-volume hospitals
Western Australian linked administrative health ; HF ; index ; AMI
Turkey
EDs ; heart failure ; ED
science ; older adults hospitalized ; HF
miRNAs ; noncoding RNAs ; binding ; messenger RNA
HFpEF ; ivabradine ; ivabradine
Cardiac c-Kit ; cells ; cardiac explant-derived cells ; cardiac functions ; myocardial infarction
NPs ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
pathophysiology ; HF ; medical management ; pathophysiologic
heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pNA
mortality ; healthcare utilization ; combinatied care management ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
inhibitor jq1 ; BETs ; chromatin ; downstream signalling ; RNA polymerase II ;Pol II
catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hFPEF
heart failure ; preserved ejection fraction ;HFpEF
cox proportional hazards regression modeling ; IE ; acute coronary syndromes ; coronary interventions
diminished cyclic adenosine monophosphate ; cAMP ; augmented cyclic guanosine monophosphate ; c gm ; hearts
RA ; methotrexate ; tNF antagonist ; non-biological disease ; antirheumatic drug ; nbDMARD
intestinal dysfunction ; disturbed intestinal barrier ; inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
sphingosine-1-phosphate receptor ; s1PR ; Î²1-adrenergic receptor ;Î²1AR ; g-protein-coupled receptors ; heart
e-septal ; pcWP ; e/e'lateral ; e/e'mean
atrial fibrillation ; carvedilol ; metoprolol
Bradycardia ; intravenous metoprolol ; cardiac sympathetic tone ; CHF-inv rabbits ; sham-inv ; CHF-DNx
Nordic walking ; standard cardiac rehabilitation ; functional capacity ; heart failure
cPG-recommended pharmacological treatment ; device consideration ; left ventricular function assessment
gLS ; LVEF ; sa ; CV events ; echocardiographic systolic parameters ; AF
ERC ; DAPc protein levels ; sarcomeric microstructure ; Skm ; myofibre regeneration
signalling cascades ; microRNAs ; bHLh transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
Rad Q66p ; inhibitory actions ; Rad ; cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
EF ;LCx ; LAD ; stenting ; left ventricle ; LCx ; LAD
EH ; LV compliance ; CH ;LV ; end-diastolic volume ; LV ; end-diastolic pressure ; hg Î² coefficient
mva ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
hART ; New York Heart association ;NYha ; HF ; self-management counseling ; death ; HF hospitalization
cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
BET ; bromodomain proteins ; bets ; acetyl-lysine reader proteins ; HF
blood transfusions ; iron ; erythropoiesis-stimulating agents ; adults ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
Grading of recommendations assessment ; development and evaluation ;GRADe
HF
right heart circulatory failure ; mechanisms of disease ; right heart
l-type voltage-gated ca(2+) channels ; ventricular action potentials ; excitation-contraction ; ec ; coupling ; myocardium
ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; preserved ejection fraction ;HFpEF
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
bNP ; glomerular filtration rate ; hypertension ; transmitral e-wave ; diastolic mitral annular velocity
AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; vasodilatory ; diuretic ; natriuretic peptides
Î²-blockade ; cAMP-dependent protein kinase ; pka ; Î²-adrenergic receptor activation
erythropoiesis-stimulating agent therapy ; benefits ; venous thromboembolism
black race ; mortality ;hospitalization ;hazard ratio ;HR ; cardiovascular mortality ;HF hospitalization
chronic myocardial ischemia ; stent ; polytetrafluoroethylene tube
genetic ; CHF ; curve ;AUc ; genetic ;AUc ; clinical
oxygen uptake ; metabolic exercise ; cardiac ; kidney index score ; HF index
heart failure ;HF ; tumor necrosis factor ;TNf ;Î± ; tNF antagonists ; HF
Centers for Medicare and Medicaid Services ; cms ; mortality ; readmission rates ; penalties
cox proportional hazard ; follow-up ; physician ; discharge
significant regression analysis ; CAD ; diameter stenosis ; left main ; CAD ; proximal left anterior descending artery
signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; chromatin structure
hypertensive HFPEF ; sodium-restricted DASh diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
mechanism ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular dilatation
Randomized aldactone Evaluation Study ; chronic advanced heart failure patients ; aldosterone antagonist ; spironolactone ; mortaliteit
heart failure ; acute myocardial infarction ; acute myocardial infarction ; Western Australia
CHF ; hCT ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
medication ; nonadherence
pathophysiological
lVAD ; albumin levels ; hypoalbuminemia
creatinine ;hazard ratio ; post-transplant mortality
glomerular filtration rate
scientific literature ; HM II ; HeartWare patients ; economic evaluations ;HM II
dopamine ; nesiritide ; renal function ; acute heart failure ; renal dysfunction
HR variability ;turbulence ; HR variability ;turbulence ; cardiac patients
lVAD therapy ; transplantation eligibility status ; device ; bt ; dt ; medical therapy
radial artery tonometry ; PH ; ICU
magnetically levitated centrifugal-flow chronic lVAS
eRK1/2 signalling ; signalosome complex ; scaffold protein ; kinases ; sequential phosphorylation
breast cancer patients ; full Medicare coverage ; breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer Registry-Medicare databases
ejection fraction ; natriuretic peptide ; heart failure ; inhospital outcomes ; get With the guideline- heart Failure Registry
cardiomyocytes ; pde2 ; cgMP synthesis ; nitric oxide donors ; pde2 inhibition ; Î²-AR responsiveness
l-dko mice ; cardiac IRS1 ; iRS2 proteins ; heart failure ; cardiac energy metabolism ; p38Î± mitogen-activated protein kinase
ecs ; HDL ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-Î²II-Ser ; p70s6k-Ser
pasp
sts ;HH ; hm ; TM ; sTS ; TM
mouse ventricular myocytes ; sarcomere
administratie ; Alberta ; discharged alive ; hospital ; heart failure
heart failure ; myocardial collagen ; tissue ; heart failure
cRT on assignment ; time to death ; HF hospitalization ;hazard ratio ; LVEF
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 cardiac gene therapy
RR ; heart failure ; bisphophonates ; crude RR ; confidence interval ;CI ; hazard ratio ;HR
hoog-cost Medicare ; fee-for-service ; Centers for Medicare ; Medicaid Services
physician adherence ; guideline recommendations ; heart failure ; Clinical practice Guideline ;CPg ; heart failure ;HF
nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; antitumor activity
ccq summary scores ; New York Heart association class ; HFpEF ; HF ; EF
Rhythm control therapy ; AF ; atrial structure ; function ; sinus rhythm ; delayed rhythm control ; rate control
acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic therapy
HF ; body composition ;skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography ; blood testing
heart failure treatment
aCP ; red blood cell transfusion ; hemoglobin threshold ; hemoglobin levels ; coronary heart disease
hospitals ; heart failure ;HF ; acute myocardial infarction ; pneumonia
left-to-right interatrial shunt ; haemodynamic outcomes ; heart failure ; ejection fraction
right ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy ; dt
Caloric restriction ; aerobic Exercise Training ; Peak oxygen Consumption ; Quality of Life ; Older Patients ; Heart Failure ; Preserved ejection Fraction
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADit-cRT trial ;Multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
Oral glucocorticoids ; HF ; HR
HR ; ivabradine group ; Ea ; TAC
carvedilol ; metoprolol ;hazard ratio ;HR
CHm ; adjunctive treatment ; dCM ; heart failure
testosterone supplementation ; exercise rehabilitation ; CHF ; testosterone status
VO2 ; lean body mass ; thigh muscle ;intermuscular fat ratio
get With the Guidelines- heart Failure ; HF ;EF ; borderline ;EF ; EF
Tools for economic analysis of Patient management Interventions in Heart Failure ; kosten-efectiveness model ; disease management programs ; heart failure
HFPSI ; death ; medical hospitalization ; HF ; clinic outpatients ; HF resources ; health systems
cardiac insulin-resistance ; mitochondrial oxidative metabolism ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
cox model analysis ; pasp ; exercise ; haard ratio ; pasp
pathophysiology ; heart failure ; preserved ejection fraction ; hFPEF ; myocardial extracellular matrix accumulation
mechanism ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular ;LV
breathing control ; cardiac arrest ; humans ; pulseless ventricular fibrillation ;pvf ; cardioverter-defibrillator device
rGK ; rem ; rem2 ; rad ; gem ;Kir ; monomeric g proteins ; ventricular action ; ec coupling ; cardiac l-type channel activity
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ;HF ; myocardial infarction
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; Î²-blocker
Swedish Web-system for enhancement and development of evidence-based care in Heart disease Evaluated According to Recommended Therapies registry ; caBG ; Sweden
LVEF ; reverse remodeling parameters ; time to death ; HF hospitalization ;hazard ratio
brain natriuretic peptide ; bNP ; bNP ; bNP
cumulative urine volume ; decongestion end point ; serum cystatin c ; enrollment ;renal function
tAPse ;longitudinal RV fiber shortening ; pasp ;force ; RV ; in vivo RV ; length-force
pde superfamily ; pde2 ; cgMP ; cAMP hydrolysis ; negative cross talk ; cgMP ; cAMP signaling
probNP ;NT-probNP ; midregional proANp ;MR-proANp ; total adiponectin ; CHF ; bmi ; FM
re-hospitalization ; admissions
mitochondrial-targeted antioxidant ; Szeto-schiller ;SS ; SS20 ; cardiac function ; proteomic remodeling
cardiac arrest ; cardiopulmonary resuscitation ; cPR ; posterior wall infarction ; cardiac centre
hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ;HF
aCP ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; insulin products
uPR ; scn5a ; ventricular systolic HF tissue samples ; induced pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
heart failure ;HF ; ejection fraction ; rEF ; renin-angiotensin system ;RAS ; Î²-blockers
cochrane Effective practice ; Organisation of Care Taxonomy
coPD ; CHF ; cRF ; ICC ; kappa coefficients
heart failure ; left ventricular ejection ; aerobic training ; dynamic resistance training ; lower limbs
implantable cardioverter-defibrillator deactivation ; implant
heart failure ; myocardial function ; dilated poorly contracting ventricles
implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator shocks
global left ventricular longitudinal systolic strain ; gLS ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ;AF
mouse Rad Q65p ; murine equivalent ; human Rad Q66p ; currents ; cav1.2 ; cav1.3 channels ; wild-type Rad
MI ; hazard ratios ;HF
Medicare ; older patients ; acute care hospital ;HF ; AMI ; pNA
cardiovascular events ; sst2 status ; BB dose ; metoprolol succinate
ctnt ; NT-probNP ; aRIC HF model ;AUcs ; NRIs
HF ; HF ; EF ; HF ; EF ; HF ; EF ; HF ; mix ; HF ; MI
ec ; HDL ;NYha-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDL
carvedilol ; Willebrand factor ; metoprolol ; Î²2-adrenergic receptor haplotype
mouse heart failure ;HF ; hypertensive heart disease ; hHD ; therapeutic targets ; hHD
sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein content ; SR ; ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
Timed up & go ; tug ; advanced chronic obstructive pulmonary disease ;coPD ; chronic heart failure ;CHf ; chronic renal failure ;crf
exercise ; intramuscular testosterone supplementation ; chronic heart failure ;CHf ; low testosterone status
HF ; LVEF ; LVEF ; LVEF
gLS ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa ; CV
heart failure ;HF ; plasmab-type natriuretic peptide ; bNP ; ejection fraction ;EF ; HF
RM ; home telemonitoring ;TM ; implanted monitoring devices ; medical support ; telephone support ; ss ; human-to-human contact ;HH ; human-to-machine interface ;HM
cox regression analysis ; beta-blockers ; beta-blockers ; antitachycardia pacing ; aTP ; shock therapy
ethically ; pediatrics ; religious beliefs ; life-sustaining treatment ; legal majority
medications ; medical records
cost ; rhythm-control ; rate-control
left ventricular ejection fraction ; eGFR
fit ; unfit ; cRF ; hazard ratios ; fit ; unfit ; overweight body mass index ; obese men
cRT ; hazard ratio ; 95% confidence interval
HFPSI model ; blood urea nitrogen ; natriuretic peptide ; New York Heart association class ; diabetes status ; atrial fibrillation ;flutter
Medicare Patient Safety monitoring system ; mSMS ; adverse event rates ; patients hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; surgery
cd34 ;vegFR2 ; cells ; functional capacity ; 10-cell ; cd34 ;vegFR2 ; cells ; VO2
treatment ; outpatients ; heart failure ; reduced ejection fraction
concurrent HF ; concurrent HF
CHF ; anthracycline exposure ; stem cell source ;allogeneic
resting tension ; fpassive-sarcomere length ; muscle strips ; kcl-KI treatment ; titin ; extracellular matrix ; fpassive
heart failure ; myocardial infarction ;MI ; Î²-adrenoceptor blockade ; infarcted rats ; metoprolol
aerobic ; resistance ; exercise capacity ; muscle strength ; cardiac ;NT-probNP ; inflammatory ;IL6 ; hscrp
readmission ; acr ; Potential Preventable Readmission ; pPR ; Centers for Medicare ; Medicaid 30-day readmission ; cms
congestive heart failure visits ; ED
walking ; Minnesota ; quality of life
arginine vasopressin ; aVP ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; Î²-blockers ; heart failure ; ejection fraction
medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; heart failure
sodium-restricted dietary ; hypertension diet ;DASh ; srd ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hFPEF
right ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTq- pcr ; interventricular septum biopsies ; beagle dogs ; heart failure
Rats ; hearts ; caspase-3 ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase 3 expression
metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor ; arg16 ; gln27 ; gly16
acute HF ; RELAx-aHF ; ASTRONAUT ; PRONTO ; patient enrollment
hospitalized HF ; international Classification of Diseases ; Ninth revision ; Clinical Modification codes ; discharge
Pulmonary capillary wedge pressure ; hg ;SD ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
Rad ; Q65p ; wild-type Rad ; Q65p substitution ; l-type channel inhibition ; rGK proteins
heart failure ; proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; HF
follow-up
heart failure ; refractory ; terminal heart failure
heart failure discharges ; University of Connecticut health Center
New York Heart association ;NYha ; Class II Heart Failure ; eplerenone ; Placebo ; Standard Heart Failure Medicines ;EMPhaSIS-HF Study
echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; IVc occlusion ; BiVP ; STE analysis ; twist ; basal rotations ; CS ; RS
drugs ; RAas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
HF ; phenylephrine ; haemodynamic stress ; transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan adults
ii-miBG cardiac washout ; carvedilol ; metoprolol treatment ; Î²2-adrenergic receptor haplotype
acute myocardial infarction ;AMI ; deaths ; heart failure ;HF ; AMI
h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; Akt ;forkhead box ; o-1 signaling ; cardiac metabolic gene expression ; ATP
bottleneck stent ; proximal left anterior descending ;LAD ; proximal circumflex artery ;LCx ; proximal LCx ; mid LAD ; pigs
postmarketing ; hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dPP-4 ; inhibitors ; antihyperglycemic agents
cox modeling ; Heart Failure Patient Severity index ;HFPSI ; University of Michigan HF clinic ;UM cohort
pde2 overexpression ; healthy cardiomyocytes ; cAMP ; l-type ca2 ; inotropic effect ; Î²-AR stimulation ; basal contractility
ATP ;HR ; inappropriate shock therapy ;HR
Cardiac resynchronization therapy ; cRT ; dialysis-dependent patients ; heart failure ;HF ; cRT ; dialysis
cardiorespiratory fitness ;crf ; body mass index ; heart failure ;HF ; mortality ; cardiovascular risk factors ; HF mortality ; fit ; unfit men
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone ; hospitalization ; SurvIval Study in Heart Failure
Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
neonatal rat ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; p38 ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ;AVd ; interventricular delay ; vd ; ste analysis ; circumferential strain ;CS ; radial strain ;RS
New York heart association ;NYha ; functional class III HF ; ejection fractions ; chronic stable guideline-directed medical therapy ;GDm
non-LBbb ; QRs ; hazard ratio
ca(2+) handling ; dyssynchronous HF ; myofiber ; septum ; myofiber ; stretch rate ; lateral wall
label-free shotgun ; proteomics ; global proteomics ; transverse aortic constriction ;TAC ; heart failure
c-Kit+ cells ; growth factor-Î² ; tGF-Î² ; epithelial ; mesenchymal transition markers ; pluripotency markers ; shams
pka ; type II regulatory ;RIiÎ± ; catalytic ; cÎ± ; subunit expression ; rIIÎ± ; ser96) ; cÎ± ; phosphorylation ;HF
hFrEF ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; RAS- ; Î²-blocker ; index HF
g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; Î²-adrenergic receptor ; postischemic heart failure
concentric remodeling ;cr ; concentric hypertrophy ;CH ; left ventricular ;LV ; remodeling ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
weight ;SD ; exercise group ;SD
RV dysfunction ;hazard ratio ; confidence interval ;CI ; cachexia ;hazard ratio
resting HR ; VO2max ; resting HR
tGF-Î² inhibition ; c-Kit+ cell phenotype ; function in vitro ; cardiac progenitor function ; cell expansion protocols
NT-probNP ; inflammatory biomarkers ; hscrp ; IL 6 ; hscrp
bets ; neurohormonally induced heart disease ; nanomolar doses ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; burden ; heart failure hospitalizations ; gm-treated NYha functional class III HF
p70s6k ; PKc-Î²II ; HDL ; nyha-IIIb ; malondialdehyde ; HDL ; nyha-IIIb ; HDL
mHF ; exercise ; diet ; exercise ; diet
nonpace ; non-DNx ; stam-Innervated ; sham-inv ; nonpace ; DNx ; sham-DNx ; pace non-DNx ; cmf-inv ; pace ; DNx ; cmf-DNx
hABC Battery score ; HF ; health ABC ; HF model ; hb ; SD ; death
ejection fraction ; frail ; biological phenotype ; frailty
hemoglobin ; hgb ; HRQoL ; HRQoL ; Heart Failure ; Exercise Training ;HF-acTION
Atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; QuÃ©bec ; rhythm ; rate-control treatment
heart failure ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
calcineurin ; nfat signalling ; miR-25 expression ; helix-loop-helix ; bHLh ; transcription factor dHAND ; hand ; human ; mouse myocardium
pss ; btes ; exercise time ; pss ; btes
NT-probNP cutoff point ; sensitiviteit ; confidence interval
prognostic power ; r-r interval oscillations ; non-linear HR variability ; fractal scaling exponent
diastolic function ; diastolic filling formalism ; relaxation ;viscoelastic ; passive ;stiffness ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; ventricular tachycardia ;HFVT ; HF patients ; spontaneous VT ;HFVT ; structurally normal hearts ; hNorm
gLS ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; sa ; CV
ventricular assist device support ; ecmo ; extracorporeal membrane oxygenation membrane support ; ecmo ; ecmo ; ecmo ; VAD
ischemic events ;IEs ; ischemic cardiomyopathy ; icc ; cardiac resynchronization therapy ; defibrillator ; cRT-d
heart failure disease management ; treatments
resistin ; heart failure ; mouse ; murine resistin ; transgenic ; Retn gene ; hum-retn mice ; inflammation-stimulated resistin ; humans
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; Î²-blockers ; devices
tttetMena ; cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation ; ambulatory Heart Failure trial ; implantable cardioverter ; defibrillator-cRT ; mortaliteit ; heart failure
heart failure patients ; Italy ; confirmatory factor analysis ; cfa ; SCHfi ;Self-Care Maintenance ; Self-Care management ; Self-Care Confidence
functional status ; mwt ; NYha class ; HFpEF ; hFrEF ; therapy ; HFpEF ; death ; HF hospitalization
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy ; male sex
Raf-MEK1/2-erk1/2 scaffold proteins ; cardiac remodelling
CHF ; SD testosterone ; nmol
functional MS ; LV dilatation ; treatment ; heart failure ;HF ; LV ; functional MS ; HF ; MR ; degenerative mitral valve
New York Heart association class ; kccq overall Summary ; symptom domains ; Spearman correlations ; HF ; EF ; HFpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; Î²-blockers ; heart failure
c57BL ; ANG II infusion ; ANG II infusion ; uninephrectomy ; ANG II infusion ; salt loading ; ANG II infusion ; uninephrectomy ; salt loading ;ANS
early transmitral blood flow velocity ; tissue ; doppler ; diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcp ; decompensated systolic heart failure ;HF
systolic indices ;LV ejection fraction ; LV strain ;strain rate ; systole ; diastolic indices ; LV strain rate ; diastole ; early transmitral flow ; sinus rhythm
VO2 ; exercise ; body mass ; diet
hazard ratios ; CI ; early-onset HF ; HF
AMI patient ; hospital ; hospital Compare
Mass spectrometry ; circulating NT-probNP ; physiological proteolysis ; leu3-gly4 ; pro6- gly7 ; pro75- arg
ctnt ; NT-probNP ; laboratory report ; ctnt ; NT-probNP ; HF
HFpEF ; New York Heart association ; mean ejection fraction
depressed left ventricular ;LV ; systolic pressure ; pressure ; ejection fraction ; fractional shortening ; cardiac output ; LV ; end-diastolic pressure ; metoprolol
baroreflex Activation Therapy ; Heart Failure With a Reduced ejection Fraction ; carotid baroreflex activation therapy ;BAT ; advanced heart failure ;HF
hazard ratio ;HR ;HR
HF ; raised blood glucose levels ; obesity ; tobacco ; systemic hypertension ;SH ; rheumatic fever ; chagas ; disease ; la
cRF ; overweight ; obese body mass index
ccq ; HFpEF ;log rank ; EF
egFR group II ; egFR group III ; egFR group IV ; uncontrolled hypertension ; diuretics ; age ; ESRD
myocardial phosphodiesterase-2 ; pde2 ; heart failure ;HF ; pde2-mediated effects ; beta-adrenergic receptor ;Î²-AR ; cardiomyocytes
heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
ERC ; epicatechin-rich cocoa ; Skm mitochondrial structure ; taub ; Ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel ; Henry
follow-up visits ; urgent readmission
TTA ; tgtetMena ; TAC surgery ; cardiac hypertrophy ; TTA ; tgtetMena ; post-TAC cardiac functional deterioration
echocardiography ; LV ; end-diastolic volume ; m2 ; MR ; mitral valve opening ; mVA ; pressure gradient
PD ; diuretic refractory ; HF ; PDrelated complications
ATP ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
New York Heart association class III heart failure ;HF ; ventricular ejection ; permanent periodic breathing ; pb
bottleneck stent ; proximal LAD ; LCx ; porcine model ; reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
Potassium ; spironolactone ; AAs
obese ;SD ; body mass index ; hFPEF
proangiogenic effects ; b ; VEGF pathway ; rats ; adenoviral vector ; decoy VEGF receptor ; ad-flk ; adenovirus ; ad-c ; treatment
post- lVAD AI ; aortic valve ; leaflet repair ; bioprosthetic aortic valve replacement ; CF lVAD ; AI
pulmonary artery systolic pressure ;PASp ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
medline ;EMBAse ; healthstar ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs institute voor reviews and Dissemination ; evidence based practice Centres
systolic heart failure ; Î²-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS ; RS synchrony ; CS ; STE ; rvPO ; RS synchrony ; CS ; BiVP ; CO
TAPse ; pasp ; tAPse-to-pasp ratio ;TAPSe ;PASp ; cox regression ; kaplan-meier analyses ;
cPET ; CHF ; exercise ; exercise
human heart failure ;HF ; mRNA splicing ; voltage-gated cardiac ; na+ channel Î±-subunit ; scn5a ; encoding truncated ; nonfunctional channels ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; heart failure ; anthracycline ; malignant disease
Tools for economic analysis of Patient management Interventions in Heart Failure ; cost-efectiveness model ; medications ; costs
natriuretic peptides ;NPs ; b-type NP ; n-terminal pro-b-type NP ; acute heart failure ; Emergency Department ;ED ; acute dyspnea
oxygen consumption ; VO2 ; vco2 slope ; exercise ; oscillatory ventilation ; eOV ; pressure ; end-tidal CO2 ;PETco2 ; cardiopulmonary exercise testing
Denmark ; bisphosphonates ; raloxifene
hypertension ; LV dilatation ; LV dysfunction ; MR ; MS ; mitral valve ; systolic ; diastolic tethering ; MR ; MS
tolvaptan ; hyponatremia ; United States ; japan ; congestive heart failure ; diuretic therapy ; sodium levels ; systolic function
longitudinal strain ; left ventricle ; echocardiographic measurements ; baseline echocardiography ; cRT ; follow-up echocardiograms
platelet-activating factor ;paf ; metabolic enzymes ; heart failure ;HF
acute care surgery ; acs ; oHT ; transplantation ; medical therapy ; mt ; intravenous inotropes ; ventricular assist devices ;VADs
HFpEF ; ivabradine ; exercise capacity ; left ventricular filling pressure ; exercise ; diastolic mitral flow velocity ; diastolic mitral annular velocity
renin-angiotensin-aldosterone system ;RAas ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
lVET ; tonometric indices
heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; Î²-blockers
cardiac performance ; Î²-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; Î²-blockers therapy
SS31 ; congestive heart failure phenotypes ; mitochondrial damage ;TAC ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein
myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; Î±-myosin heavy chain ; mRNA level ; Î²-myosin heavy chain ; metoprolol
HDL ;healthy ; CHF-NYha-III ;HDL ;NYha-IIIb ; eth ; CHF-NYha-II ;HDl ;NYha-II
inesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
mDC ; confidence level ; mDC ; mDC ; 95% confidence level ; mDC
heart failure ; contrast agent ; after contrast agent administration
HF ; LA ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
ST2 ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; controlled trial Investigating Outcomes of Exercise Training ;HF-acTION ; exercise training ; HF
cardiopulmonary exercise testing ; exercise rehabilitation ; patients with chronic heart failure ; chronic heart failure ;CHf ; CardioPulmonary Exercise testing ; cPET ; exercise rehabilitation ; China
AA ; ischemic HF pathogenesis ; NYha functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
HF-action ; exercise training ;HF ; low left ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire ; kccq
cRT ; systolic dysfunction ; resynchronization reverses remodeling in Systolic left v entricular dysfunction ; reverse ; left ventricular ;LV ; ejection fraction ;LVEF
glomerular filtration rate ; egFR ; diabetes ; total cholesterol ; lDL-cholesterol ; CLcnka gg genotype
echocardiography ; LV ; end-diastolic dimension ; LV ; end-diastolic pressure ;wall stress ; lung weight ; untreated aCF ; sham group
diagnosti performance ; s'lateral ; aUC
spironolactone
cardiac procedures ; cardioversions ; kosten ; antiarrhythmic drugs ;CAD
diabetes mellitus ; cardiomyopathy origin ; Î²-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone post myocardial infarction ; Heart failure Efficacy ; survival Study ; euras ; post-myocardial infarction ; heart failure ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADit-crt ; multicenter Automatic Defibrillator Implantation With Cardiac resynchronization Therapy
HR ; heart failure-related mortality ; sudden death ; HR
DASh ; srd ; brachial systolic pressure ; centrale end-systolic pressure
HF ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
HF ; LVEF ; Heart Failure Survey ; israel
left ventricular ejection fraction ; world health Organization criteria ; idiopathic dilated cardiomyopathy ; negative coronary angiography
europese Society of Cardiology guidelines ; hFPEF ; heart failure ; LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ; LV relaxation ; diastolic stiffness ; LV filling pressures
Î²1ARs ; s1PR1s ; myocyte ; cAMP production ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
follow-up ; PAf-cPT ; PAF ; lyso-paf-AT ; paf-AH ; lp-PLA2
heart failure ; ejection fraction ; standard cardiac rehabilitation ; Nordic walking
dRS-stratified hazard ratios ; ci ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; ci ; sitagliptin ; insulin
skeletal muscle mass ; t-score ; Fontan ; sarcopenic range ; muscle wasting ; t-score
testosterone group ; oxygen uptake ; Beck depression inventory ; leg strength ; Medical Outcomes Study Short-Form quality of life domains ; exercise ; placebo group
RAS- ; Î²-blocker uptitrations ; all-cause mortality ; HF ; readmissions ; hFrEF ;hazard ratio ;HR ; confidence interval ; ci
Heart Failure ; trial Investigating Outcomes of Exercise Training ;HF-action ; social support ; barriers to exercise ; psss ; barriers to exercise score ; btes
ST2 ; cardiovascular death ; HF hospitalization ;hazard ratio ; all-cause mortality ;hazard ratio ; log2
New York heart association ; Fontan adults ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
dopamine ; nesiritide ; diuretic ; renal function ; acute heart failure ; renal dysfunction
cRT ; New York Heart association class III ; heart failure ; left ventricular ejection ; QRs ; echocardiographic ; left ventricular dyssynchrony
left ventricular ;LV ; ejection fraction ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus velocities ; systole ; diastole
acute coronary syndromes ; CAD ; bNP ; NT-probNP ; CAD
HF ; lyso-paf-at ; paf-cpt ; PAf ; PAf-AH ; lp-PLA2
redo sternotomy ; aortic valve procedures ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve procedure ; open surgery ; aortic valve replacement
plasma ; pro-b-type natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; emergency department ;ED
cardiac troponin t ; ctnt ; assay ; n-terminal pro-b-type natriuretic peptide ;NT-probNP ; biomarkers ; incident HF ; HF ; Atherosclerosis Risk in Communities ;ARIc
body mass index ;HR ; fat mass ; fat-free mass index
interquartile range ; body mass index ;interquartile range ; COPd ; CHF ; cRF
reverse remodeling ; ejection fraction ; mortality ; HF ; dialysis patients
EH ; LV contractility ; CH ; LVEF ; significant ; systolic blood pressure ; end-systolic volume ;Î² coefficient
echocardiography ; LV ; end-diastolic volume index ; mL ; m2 ; LV ; ejection fraction ; MR ; mitral valve opening ; MS ; mVA ; pressure gradient
renal Optimization strategies Evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration rate
bets ; chromatin-mediated signal transduction ; Pol II ; transcription factor networks ; HF pathogenesis ; nuclear factor of activated T cells ; nFAT ; nuclear factor-Îºb ;NF-Îºb ; transcription factor gATA4
cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
cardiovascular mortaliteit ; hazard ratio
EO-cFUs ; diabetes ; eu-cFU ; EO-cFU ; VO2 ; diabetes ; EO-cFUs ; VO2
immunoblotting ; radioenzymatic- ; fluorescence resonance ; energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; ca2 ; myocardial tissues ; isolated cardiomyocytes ; hb
east ; Atrial fibrillation ; Stroke prevention trial ; AF ; stroke ;CHA2DS2VASc score ; usual care ; early rhythm control therapy
Exercise capacity ; oxygen consumption ;VO2 ; QOL ; Minnesota Living with Heart Failure ;MLHF ; Questionnaire ; heart failure-related QOL
TAC-induced proteomic alterations ; mitochondrial-targeted peptide SS31 ; mitochondrial function ; TAC ; mitochondrial-targeted peptide drugs ; heart failure
low left ventricular ejection fraction ; HF ; preserved left ventricular ejection fraction ; hospital ; physicians
HF patients ;HFrEF ; left ventricular ;LV ; ejection fraction ;HFpEF ; echo-Doppler studies ; pro-brain-type natriuretic peptide
low-volume EDs ; hospitalized ; medium-volume EDs ; aOR
cardiac transplant ; ecCT ; diabetes mellitus ; chronic kidney disease ; glomerular filtration
hABC Battery scores ; health ABC HF Risk model ; discrimination ; c-index ; reclassified ; HF
cfi ; RMsea ; Self-Care Maintenance Scale ; cfi ; RMsea ; Self-Care management Scale ; cfi ; RMsea ; Self-Care confidence scale
BAT ; quality-of-life score ; nyha functional class ranking
hypoalbuminemia ; postoperative ; albumin levels ; hypoalbuminemia ; albumin levels ; lVAD
rehospitalization ; acute myocardial infarction ;AMI ; complications ; kidney infection ; urinary tract infection ;UTI
heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; left ; ventricular assist devices
SAF ;PF ; centrale venous pressure ; hg ; sVR index ; dyn ; cardiac index
admission median ; bNP ; EF ; preserved EF ; bNP ; EF
heart failure admission ; heart transplantation ;LV assist device ; death ;hazard ratio ; death
ejection fraction ; circumferential shortening ; systolic elastance ; contractile efficiency ; acf ; allopurinol rats ; o2 consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
HFpEF ; LV structure ; normal geometry ; LV hypertrophy ;LVh ; relative wall thickness ;RWt ; CR ; LVh ; rwt ; CH ;LVh ; rwt ; eh ;LVh ; rwt
lCZ696 ; angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor ; prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; preserved ejection fraction ; heart failure ; ejection fraction
blood pressure ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio ring ;Edwards lifesciences ; irvine
shuttle walk test ; oxygen uptake ; muscular strength ; echocardiographic measures ; natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ;Minnesota Living with Heart Failure Questionnaire ; Medical
LVEF ;HR ; long-term mortality ; preserved ; LVEF
westar-kyoto ; lean zSF ; obese zSF ; zSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
kaplan-meier curves ; log-rank testing ; UM/VA/ va-RT cohorts
multivariate cox regression analyses ; AF type ; hypertension ; sinus rhythm ;hazard ratio ;HR ; confidence interval ; ci ; HR
chronic HF-ref ; NYha functional class II ; egFR ; potassium ; eplerenone ; hyperkalemia ; wRF
fm ; FM ; body fat distribution ; dual energy X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;cc ; non-cachectic CHF ; myocardial infarction-both
spironolactone ; sterf ; hospitalization ; HF ; haard ratio ; AAs ;hazard ratio
pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; right ventricular pump ; pulmonary arterial hypertension ; medication ; stress echocardiography ; cardiopulmonary exercise
cardiovascular death ; HF hospitalization ; btes ; cardiovascular death ; HF hospitalization ; exercise group ;hazard ratio
index ED visit ; low-volume ED ; readmission ; medium ; aOR ; high-volume EDs ; aOR
implantable cardioverter-defibrillator deactivation ; implantation ; cardioverter-defibrillator deactivation
Cardiac magnetic resonance ; left atrial area ;hazard ratio ; pulmonary vascular resistance
HF units ; systolic ; left ventricular ejection fraction ; HF ; New York Heart association ; echocardiographic ; cardiopulmonary exercise test
heart failure ; ABCd classification ; American college of Cardiology ; acc ;American heart association ;AHA ; New York Heart association ;NYha ; structural heart disease ; heart failure
mva ; continuity equation ;LV ; end-diastolic volume ; LV end-systolic volume ; mitral filling flow volume ; mva ; velocity time integral ; mitral filling flow ; continuous wave ; doppler echocardiography ; MR ; mitral valve plasty
rm ; mortality ; sts HH ; cri ; TM ; office hours ; rm
HFPSI ; Ann arbor Veterans Affairs ; HF clinic ; va cohort ; HFPSI ; va-RT cohort ; va patients ; HFPSI
AAs ; spironolactone dose ; hyperkalemia ;potassium ; hypokalemia ;potassium
LVEF ; long-term mortality ; LVEF ;hazard ratio ;HR ; LVEF ; preserved LVEF ;HR
HFpEF ;odds ratio ; nyha class III ; nyha ; walk test ; mwt
pulmonary arterial systolic pressure ;PASp ; right ventricular ;RV ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
CAD ; diabetes ; electrocardiographic Q waves ; left bundle branch block ; nondiabetes risk factors ; dyslipidemia ; hypertension ; tobacco use
receiver operating characteristic curve ;AUc ; pcWP ; confidence interval ;CI ; e-septal ; e/elateral ; e/emean
trastuzumab-treated patients ; coronary artery disease ;HR ; hypertension ;HR ; weekly trastuzumab administration ; CHF
LVEF ; clinical composite response ; cRT on ; cRT OFF ; LV end systolic volume index ; LV mass
tGF-Î² signaling ; tGF-Î² receptor type I ; smad ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit+ cell differentiation ; cardiomyocyte-like cells
hFrEF ; diuretics ; co-morbidities ; wt ; nyha class III
HF ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; mitral valve area ; mVA ; pressure gradient
systolic heart failure ;ejection fraction ; ivabradine ; SHIft ; systolic Heart Failure Treatment ; If inhibitor ivabradine trial ; ivabradine ; echocardiographic substudy
Hazard ratios ; pb ; pb ;hazard ratio ; pb ; tAPse ; New York Heart association functional class
Renal function ; Chronic Kidney Disease Epidemiology Collaboration equation ; glomerular filtration rate ; egFR
paradigm-HF ; chronic heart failure ; systolic dysfunction ;LV EF ; functional class NYha II-III ; bNP ; bNP ; cardiovascular death ; hospitalization ; heart failure ; arni ; lz696 ; sacubiltril ; valsartan
LV reverse remodeling ; pre-cRT LV ; end-diastolic dimension index ; global longitudinal strain ; left ventricle ; left atrial area ; right ventricular end-diastolic area index ; right atrial area ; right ventricular fractional area
hyperkalemia ; African Americans ; AAs ; non-AAs ; white ; New York Heart association ;NYha ; class III ; HF ; left ventricular dysfunction ; spironolactone ; aldactone Evaluation Study ;RALes
iRS1 ; iRS2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS2 ; iRS1 ; iRS2 gene double-knockout ; l-dko ; liver-specific IRS1 ; iRS2 double-knockout ; l-dko
b-type natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; coronary artery disease ; natriuretic peptide ; bNP ; n-terminal fragment ;nt-probNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile range ; Î²-blockers
ivabradine ; diastolic mitral flow velocity ; diastolic mitral annular velocity ; exercise capacity ; ivabradine ; oxygen uptake
liberal transfusion protocols ; mortality rates ; aggressive protocols ; i2 ; mortality rates ; acute coronary syndrome
unplanned readmission ; familiar physician ; hazard ratio ;HR ; confidence interval ;CI ; unfamiliar physician
hek ;human embryonic kidney ; cells overexpressing ; Î²1AR ; s1PR1 ; Î²1AR ; downregulation ; sphingosine-1-phosphate ; s1PR1 agonist ; isoproterenol ; Î²-adrenergic receptor agonist
kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; zung self-rated depression scores ; natriuretic peptide ; endothelial function ; ventricular diastolic function
cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration rate ; kidney injury
diastolic function ; Ea ; ventricular-arterial coupling
disease risk score ; dRS ; ci ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
i ; revascularization ; coronary artery bypass surgery ; hazard ratio ;HR ; percutaneous coronary intervention ; HR ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram ; IE
biomedical treatment ; biomedical treatment ; CHm ; left ventricular ejection fraction ; left ventricular diastolic end diameter
open-label crossover study ; heart failure patients ; left ventricular ejection fraction ; arg16 ; gln27 ; gly16 ; lim27 haplotype ; Î²2-receptor ; carvedilol ; metoprolol
low-volume ED cases ; death ;hospitalization ;ED visit ; aOR ; high-volume ED ; aOR
Health Buddy Program ;hazard ratio ;HR ; confidence interval ;CI ; inpatient admissions
multivariable-adjusted hazard ratios ; Mediterranean diet score ; DASh
ctnt ; NT-probNP ;laboratory report ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; HF ; receiver operating characteristic curve ;AUc ; discrimination improvement ; net reclassification improvement ; nRI
eplerenone ; hyperkalemia ; renal function ; wRF ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ;HF-ref ; New York Heart association ;NYha ; glomerular filtration rate ; e gFR ; serum potassium
nesiritide ; cumulative urine volume ;nesiritide ; mL ; placebo ; cystatin c level ;nesiritide
Nordic walking ; functional capacity ; wt ; physical activity ; right grip strength ; kg ; depressive symptoms ;Hospital anxiety and depression Scale
hyperkalemia ; wRF ; diabetes ; egFR ; systolic blood pressure ; hg ;potassium ; hyperkalemia ; wRF ; cardiovascular mortality
PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-at ; dithiothreitol ; dt ; cdp ; choline ; 1-alkyl-2-acetyl-sn-glycerol ; cholinephosphotransferase ; pbf-cPT ; catabolic isoenzymes ; paf-acetylhydrolase ; paf-AH ; lipoprotein-associated phospholipase ; lp-PLA2]
ivabradine group ; follow-up exercise capacity ; oxygen uptake ; early diastolic mitral flow velocity ; diastolic mitral annular velocity
CHF ;Odds Ratio ; hbf ; chest radiation ; hypertension ; NAD(ph-oxidase subunit RAC2 ; gbf ; doxorubicin efflux transporter ABCc2
NYha classification ; class II ; class III ; class I ; patient ; quality of life ; Duke Activity status index ; Kansas City Cardiomyopathy Questionnaire
low-dose dopamine ; cumulative urine volume ;dopamine
haard ratio ;HR ; confidence interval ;CI ; baseline glomerular filtration rate ;HR ; chronic obstructive pulmonary disease ; diabetes ;HR ; peripheral vascular disease ; left ventricular ejection fraction ; h ; iCD shocks ; New York Heart association class ; atrial fibrillation ; congestive HF
oxygen uptake ; hazard ratio ;HR ; confidence interval ;CI ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
Kansas City Cardiomyopathy Questionnaire summary ; Minnesota Living with Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; fes group ; natriuretic peptide ; mitral e/e wave ratio
